WO2024105271A1 - Préparation d'héparine à poids moléculaire moyen - Google Patents

Préparation d'héparine à poids moléculaire moyen Download PDF

Info

Publication number
WO2024105271A1
WO2024105271A1 PCT/EP2023/082300 EP2023082300W WO2024105271A1 WO 2024105271 A1 WO2024105271 A1 WO 2024105271A1 EP 2023082300 W EP2023082300 W EP 2023082300W WO 2024105271 A1 WO2024105271 A1 WO 2024105271A1
Authority
WO
WIPO (PCT)
Prior art keywords
mmwh
red
molecular weight
medium molecular
weight heparin
Prior art date
Application number
PCT/EP2023/082300
Other languages
English (en)
Inventor
Pervinder Singh BHOGAL
John Brackett
Graham RUSHTON
Original Assignee
Glycos Biomedical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycos Biomedical Ltd filed Critical Glycos Biomedical Ltd
Publication of WO2024105271A1 publication Critical patent/WO2024105271A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/10—Heparin; Derivatives thereof

Definitions

  • the present invention relates to the synthesis of medium molecular weight heparins, preferably via low temperature periodate oxidation.
  • Heparin is a naturally occurring, highly sulphated polysaccharide characterised by a wide molecular weight range of polysaccharide chains. Heparin acts at a variety of different ligands with varied actions. Heparin is a member of the glycosaminoglycan carbohydrate family and consists of repeating disaccharide units of GlcApi-4GlcNAcal-4 with poly-disperse sulfation, N-acetylation and uronosyl epimerization. Heparin is highly heterogenous. Heparin isolated from natural sources contains polysaccharide chains with molecular weights ranging from about 3000 Da (g/mol) to about 30,000 Da (g/mol).
  • UFH unfractionated heparin
  • UFH can be enzymatically or chemically treated to deliver shorter polysaccharide chains.
  • Heparinase I cleaves at the a-1,4 linkage between nonacetylated GlcNS6S and ldoA2S.
  • the products of the chemically or enzymatically treated UFH can be affinity purified to yield fractionated heparin where the molecular weight of the polysaccharides in each fraction can be readily determined.
  • Low molecular weight heparin (LMWH) contains polysaccharide chains in the range of about 4000 Da (g/mol) to about 8000 Da (g/mol).
  • the invention provides a method of synthesis of medium molecular weight heparin, the method comprising the steps of: (a) dissolving unfractionated heparin in an aqueous buffer solution adjusted to between about pH 5.0 and about pH 9.0 to provide a first solution; (b) adding an oxidising agent to the first solution to provide a second solution; and (c) incubating the second solution at a temperature of from about 0 °C to about 10 °C to form a medium molecular weight heparin solution.
  • the invention provides a kit suitable for preparing medium molecular weight heparin, wherein the kit comprises: (a) unfractionated heparin; (b) an aqueous buffer solution adjusted to between about pH 5.0 and about pH 9.0; (c) an oxidising agent; and (d) optionally, an inactivating agent.
  • the invention provides a method of preparing reduced medium molecular weight heparin (MMWH-Red) comprising (a) dissolving unfractionated (UF) heparin in an aqueous buffer solution adjusted to between about pH 5.0 and about pH 9.0 to provide a first solution; (b) adding an oxidising agent to the first solution to provide a second solution; (c) incubating the second solution at a temperature of from about 0 °C to about 10 °C to form a medium molecular weight heparin solution; and (d) incubating the medium molecular weight heparin with a reducing agent to produce MMWH-Red.
  • the invention provides reduced medium molecular weight heparin (MMWH-Red).
  • MMWH-Red is prepared according to the first or third aspect of the invention.
  • the invention provides the invention provides reduced medium molecular weight heparin produced according to the following steps: (a) dissolving unfractionated (UF) heparin in an aqueous buffer solution adjusted to between about pH 5.0 and about pH 9.0 to provide a first solution; (b) adding an oxidising agent to the first solution to provide a second solution; (c) incubating the second solution at a temperature of from about 0 °C to about 10 °C to form a medium molecular weight heparin solution; and (d) incubating the medium molecular weight heparin with a reducing agent to produce reduced medium molecular weight heparin. [010] In a sixth aspect, the invention provides a composition comprising reduced medium molecular weight heparin.
  • the invention provides reduced medium molecular weight heparin according to the fourth or fifth aspect of the invention or a composition according to the sixth aspect of the invention for use in the treatment of endotheliopathy.
  • the invention provides reduced medium molecular weight heparin for use in the treatment of a disease or condition in a patient, wherein the patient has an endotheliopathy characterised by a plasma von Willebrand factor to ADAMTS13 (VWF:ADAMTS13) ratio of at least about 2.
  • VWF:ADAMTS13 plasma von Willebrand factor to ADAMTS13
  • the invention provides reduced medium molecular weight heparin for use in the treatment of a disease or condition in a patient, wherein the patient has an endotheliopathy characterised by a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • VWF antigen:ADAMTS13 a plasma von Willebrand factor antigen to ADAMTS13
  • the invention provides a method of treating endotheliopathy, the method comprising administering to a subject in need of treatment a therapeutically effective amount of reduced medium molecular weight heparin.
  • a therapeutically effective amount of reduced medium molecular weight heparin Preferably, wherein the patient has plasma VWF:ADAMTS13 ratio of at least about 2.
  • the invention provides the use of the reduced medium molecular weight heparin for the manufacture of a medicament for the treatment of endotheliopathy in a patient.
  • the patient has plasma VWF:ADAMTS13 ratio of at least about 2.
  • the invention provides the use of the reduced medium molecular weight heparin for the manufacture of a medicament for the treatment of endotheliopathy in a patient.
  • the patient has plasma VWF antigen:ADAMTS13 ratio of at least about 2.
  • Figure 1 shows MMWH prepared at 4 °C compared to heparin treated at 37 °C, untreated heparin and a 11 kDa standard.
  • Figure 2 shows MMWH prepared at 4 °C using only periodate compared to heparin treated with periodate then NaOH at 4 °C.
  • treatment and “therapy” define the therapeutic treatment of a patient, in order to reduce or halt the rate of progression of a disorder or condition, or to ameliorate or cure the disorder or condition. Prophylaxis of a disorder or condition as a result of treatment or therapy is also included.
  • the term "patient” preferably refers to a mammal. Typically, the mammal is a human.
  • VWF von Willebrand factor
  • a blood glycoprotein involved in haemostasis is a blood glycoprotein involved in haemostasis.
  • VWF is a large multimeric glycoprotein present in blood plasma and produced constitutively as ultra-large VWF in endothelium (in the Weibel-Palade bodies), megakaryocytes (a-granules of platelets), and subendothelial connective tissue.
  • the basic VWF monomer is a 2050-amino acid protein.
  • a disaccharide is a sugar whose molecules contain two monosaccharide residues.
  • a low molecular weight heparin is defined herein as a heparin with an average molecular weight of from about 4000 Da (g/mol) to about 8000 Da (g/mol).
  • a medium molecular weight heparin is defined herein as a heparin with an average molecular weight of from greater than about 8000 Da (g/mol) to about 13000 Da (g/mol).
  • the invention provides a method of synthesis (or preparation) of medium molecular weight heparin (MMWH).
  • MMWH medium molecular weight heparin
  • the medium molecular weight heparin prepared by the method of the first aspect of the invention may have a mass in the range of greater than about 8000 Da (g/mol) to about 13 000 Da (g/mol), preferably about 10 000 Da (g/mol) to about 12 000 Da (g/mol).
  • the medium molecular weight heparin prepared by the method of the first aspect of the invention may have a mass of about 11 000 Da (g/mol).
  • the medium molecular weight heparin prepared by the method of the first aspect of the invention may comprise polysaccharide chains with an average molecular mass in the range of about 8000 Da (g/mol) to about 13 000 Da (g/mol), preferably about 10 000 Da (g/mol) to about 12 000 Da (g/mol).
  • the medium molecular weight heparin prepared by the method of the first aspect of the invention may comprise polysaccharide chains with an average molecular mass of about 11 000 Da (g/mol).
  • the molecular weight of the medium molecular weight heparin prepared by the method of the first aspect of the invention may be determined by size exclusion chromatography as described herein.
  • the medium molecular weight heparin prepared by the method of the first aspect may comprise at least three units of a GlcNS6S-ldoA2S (or ldoA2S-GlcNS6S) disaccharide.
  • the GlcNS6S and ldoA2S monosaccharides are linked by an al-4 linkage between GlcNS6S and ldoA2S, i.e. GlcNS6Sal- 4ldoA2S.
  • the medium molecular weight heparin prepared by the method of the first aspect may comprise at least four units, preferably at least five units, preferably at least six units, preferably at least eight units, preferably at least ten units of a GlcNS6S-ldoA2S disaccharide.
  • the medium molecular weight heparin prepared by the method of the first aspect may comprise less than or equal to 25 units of the GlcNS6S-ldoA2S disaccharide, for example less than or equal to 20 units.
  • the presence of the units of the GlcNS6S-ldoA2S disaccharide may be determined by an antibody, mass spectrometry, or inferred from chemical and enzymatical studies.
  • the GlcNS6S-ldoA2S units may be ordered in succession.
  • IdoA is a-L-iduronic acid.
  • LdoA2S is IdoA modified by the addition of an O-sulfate group at carbon position 2 to form 2-O-sulfo-a-L-iduronic acid.
  • GIcNS is 2-deoxy-2-sulfamido-a-D- glucopyranosyl.
  • GlcNS6S is 2-deoxy-2-sulfamido-a-D-glucopyranosyl-6-O-sulfate.
  • An al-4 linkage is an alpha glycosidic bond between carbon-1 on one monosaccharide and carbon-4 on a second monosaccharide.
  • the medium molecular weight heparin prepared by the method of the first aspect may comprise UA2S-GlcNS6S, UA2S-GlcNS, UA-GIcNAc, wherein U may be iduronic acid (IdoA) orglucuronic acid (GlcA).
  • the medium molecular weight heparin prepared by the method of the first aspect may comprise at least about 60% UA2S-GlcNS6S, UA2S-GlcNS, and UA-GIcNAc.
  • the medium molecular weight heparin prepared by the method of the first aspect may comprise at least about 45%, preferably at least about 48%, preferably at least about 49%, preferably at least about 60% UA2S- GlcNS6S.
  • the medium molecular weight heparin prepared by the method of the first aspect may comprise up to about 60%, preferably up to about 70%, preferably up to about 85% UA2S-GlcNS6S.
  • the medium molecular weight heparin prepared by the method of the first aspect may comprise at least about 4%, preferably at least about 5%, preferably at least about 6%, preferably at least about 10% UA2S-GlcNS.
  • the medium molecular weight heparin prepared by the method of the first aspect may comprise up to about 15%, preferably up to about 20% UA2S-GlcNS.
  • the medium molecular weight heparin prepared by the method of the first aspect may comprise at least 4%, preferably at least 5%, preferably at least 6%, preferably at least about 10% UA-GIcNAc.
  • the medium molecular weight heparin prepared by the method of the first aspect may comprise up to about 15%, preferably up to about 20% UA-GIcNAc.
  • the medium molecular weight heparin prepared by the method of the first aspect may comprise at least 49.2% UA2S-GlcNS6S, 5.4% UA2S-GlcN and 5.4% UA-GIcNAc. In some embodiments the medium molecular weight heparin prepared by the method of the first aspect may comprise at least 82% UA2S-GlcNS6S, 9% UA2S-GlcNS and 9% UA- GIcNAc. The percentage composition of UA-GIcNAc comprised in the medium molecular weight heparin may be enriched compared to unfractionated heparin.
  • U is a uronic acid, which is a hexose with a negatively charged carboxylate at the 6-position.
  • the uronic acid may independently be glucuronic acid or iduronic acid.
  • U2S is UA modified by the addition of an O-sulfate group at carbon position 2 to form 2-O-sulfo-uronic acid.
  • GlcA is P-D- glucuronic acid
  • GIcNAc is 2-deoxy-2-acetamido-a-D-glucopyranosyl.
  • the method of the first aspect comprises the following steps: (a) dissolving unfractionated (UF) heparin in an aqueous buffer solution adjusted to between about pH 5.0 and about pH 9.0 to provide a first solution; (b) adding an oxidising agent to the first solution to provide a second solution; and (c) incubating the second solution at a temperature of from about 0 °C to about 10 °C to form a medium molecular weight heparin solution.
  • UF heparin may be obtained from bovine or porcine tissue, for example porcine intestine or bovine lung.
  • Buffer refers to a chemical which, in a solution, resists a change in pH when acid or alkali is added to the solution.
  • a buffer solution or buffer system
  • a buffer solution comprises a weak acid and its conjugate base, or a weak base and its conjugate acid.
  • a suitable buffer comprises an acid with a pKa value that lies within ⁇ 1 of the desired pH of the formulation.
  • a suitable buffer comprises a weak acid with a pKa value of from about 6.0 to about 8.0. If the acid of a buffer has more than one pKa value (i.e. each molecule of the acid is able to donate more than one proton), in order for the buffer to be suitable, at least one of the pKa values should lie within the desired pH range.
  • the weak acid and conjugate base (or weak base and conjugate acid) of the buffer are in equilibrium with one another.
  • a constraint such as a change in concentration of a reactant
  • addition of acid or base to the solution shifts the position of equilibrium in favour of the conjugate base or weak acid, respectively. Consequently, the concentration of free protons in the formulation (and thus the pH) is relatively unchanged.
  • Phosphate buffered saline may also be used.
  • the pKa values cited herein are those reported at 25 °C in water.
  • the buffer comprises only one of the pairs listed above, i.e. one acid and its conjugate base.
  • the buffer may comprise an acetate salt and acetic acid, a citrate salt and citric acid, or a phosphate salt and phosphoric acid.
  • the pH is adjusted to ensure that the pH of the first solution is between from about pH 5.0 to about pH 9.0 because dissolving unfractionated heparin may result in the pH of the aqueous buffer solution changing.
  • the aqueous buffer solution is adjusted to between about pH 6.0 and about pH 8.0, more preferably to about pH 7.0.
  • the temperature of the aqueous buffer solution in step (a) is from about -2 °C to about 4 °C.
  • the temperature of the aqueous buffer solution in step (a) is from about 0 °C to about 2 °C.
  • the aqueous buffer solution is a phosphate buffer, a citrate buffer or an acetate buffer, i.e. the buffering system is phosphate, citrate or acetate.
  • the aqueous buffer solution is a phosphate buffer, more preferably the aqueous buffer solution is a sodium phosphate buffer or a potassium phosphate buffer, i.e. the buffering system is sodium phosphate or potassium phosphate.
  • the buffering system in the aqueous buffer solution may be present at a concentration of from about 10 mM to about 100 mM, more preferably from about 20 mM to about 90 mM, more preferably from about 30 mM to about 80 mM, more preferably from about 40 mM to about 70 mM, more preferably from about 50 mM to about 60 mM.
  • the buffering system in the aqueous buffer solution may be present at a concentration of about 50 mM.
  • the concentration of UF heparin in the aqueous buffer solution may be from about 0.5 mg/mL to about 10 mg/mL, more preferably from about 1 mg/mL to about 8 mg/mL, more preferably from about 1.5 mg/mL to about 6 mg/mL, more preferably from about 2 mg/mL to about 4 mg/mL.
  • the concentration of UF heparin in the aqueous buffer solution may be about 1.5 mg/mL, more preferably about 1.8 mg/mL, more preferably about 2 mg/mL, more preferably about 2.5 mg/mL, more preferably about 2.7 mg/mL, more preferably about 3 mg/mL.
  • the oxidising agent may be a periodate, for example sodium periodate or potassium periodate.
  • the oxidising agent is sodium periodate.
  • the oxidising agent may be a perchlorate, for example sodium perchlorate.
  • the oxidising agent does not comprise a perchlorate. Use of a perchlorate in combination with a periodate as the oxidising agent results in an increased level of sample breakdown to smaller molecular weight species.
  • the concentration of the oxidising agent in the aqueous buffer solution may be from about 1 g/L to about 10 g/L.
  • the concentration of the oxidising agent may be from about 2g/L to about 9 g/L, more preferably from about 4 g/L to about 8 g/L, more preferably from about 5 g/L to about 7 g/L.
  • the concentration of oxidising agent is about 5.7 g/L.
  • the concentration of the oxidising agent is 5.7 g/L and the oxidising agent is sodium periodate.
  • the molar ratio of UF heparin to oxidising agent may be from about 1:1 to about 1:200, more preferably from about 1:2 to about 1:150, more preferably from about 1:10 to about 1:100, more preferably from about 1:20 to about 1:50, more preferably from about 1:30 to about 1:40.
  • the molar ratio of UF heparin to oxidising agent may be about 1:40.
  • the incubation temperature in step (c) is from about 0 °C to about 10 °C, more preferably from about 1 °C to about 9 °C, more preferably from about 2 °C to about 8 °C, more preferably from about 3 °C to about 7 °C, more preferably from about 4 °C to about 6 °C.
  • the incubation temperature in step (c) is about 4 °C.
  • step (c) is carried out for from about 1 hour to about 48 hours, more preferably from about 4 hours to about 36 hours, more preferably from about 8 hours to about 30 hours, more preferably from about 12 hours to about 24 hours, more preferably from about 15 hours to about 20 hours, more preferably from about 16 to about 18 hours.
  • step (c) may be carried out at from about 20 to about 25 °C.
  • Incubation step (c) of the first aspect of the invention may be carried out in a laboratory fridge set at the required temperature.
  • the laboratory fridge may be set at a temperature of from about 0 °C to about 10 °C, more preferably from about 2 °C to about 8 °C, more preferably from about 3 °C to about 7 °C, more preferably from about 4 °C to about 6 °C.
  • the laboratory fridge may be set at a temperature of about 4 °C.
  • the method of the first aspect may further comprise step (d), the step of inactivating the oxidising agent in the medium molecular weight heparin solution.
  • the oxidising agent may be inactivated by the addition of an inactivating agent selected from the group consisting of: D-mannitol, glycerol, /V-acetylmethionine, sodium sulfite, and combinations thereof.
  • an inactivating agent selected from the group consisting of: D-mannitol, glycerol, /V-acetylmethionine, sodium sulfite, and combinations thereof.
  • a particularly preferred inactivating agent is D-mannitol.
  • the molar ratio of the oxidising agent to the inactivating agent may be from about 1:1 to about 1:10, more preferably from about 1:2 to about 1:8, more preferably from about 1:3 to about 1:6, more preferably from about 1:4 to about 1:5. Typically, the molar ratio of the oxidising agent to the inactivating agent may be about 1:2 or about 1:4.
  • the method of the first aspect may further comprise step (e), the step of dialysing the medium molecular weight heparin solution in a dialysate to provide a dialysed medium molecular weight heparin sample.
  • “Dialysis” or “dialysing” means the process of separating molecules in solution by the difference in their rates of diffusion through a semipermeable membrane, for example dialysis tubing.
  • the sample for dialysis and a dialysate (or buffer) are placed on opposite sides of the semipermeable membrane.
  • Target sample molecules e.g. proteins, DNA or polysaccharides
  • Contaminants such as small molecules and salts can pass through the membrane into the dialysate, thereby reducing the concentration of contaminants in the sample to low levels.
  • Changing the dialysate for fresh dialysate removes the contaminants that have passed from the sample to the dialysate. This allows more contaminants to diffuse from the sample into the dialysate.
  • Dialysis can separate small molecules such as salts, reducing agents, or dyes, from larger macromolecules such as proteins, DNA or polysaccharides. Dialysis can also be used to separate polysaccharides by molecular weight.
  • the semipermeable membrane is typically made of a film of regenerated cellulose or cellulose esters.
  • Dialysis may be carried out by placing a dialysis tubing containing a sample in a dialysate.
  • a "dialysate" is the fluid into which material passes from the dialysis tubing.
  • the dialysate may be refreshed as often as necessary to achieve optimum separation.
  • the dialysis may be carried out over a period of about 1 day to about 14 days, preferably about 5 days to about 10 days, preferably about 7 days.
  • the dialysate may be refreshed about 1 time a day to about 10 times a day, preferably about 2 times a day to about 5 times a day, preferably about 3 times a day.
  • the dialysate is many times the volume of the sample, for example from about 2 to about 500 times the volume of the sample.
  • the dialysate may be about 4 times the volume of the sample.
  • the dialysate is water.
  • the dialysate may comprise electrolytes such as sodium, potassium, magnesium, calcium, chloride, bicarbonate, lactate, glucose, amino acids, or combinations thereof.
  • the dialysing step (e) may be carried out in 2 kD cut off tubing, for example provided by Spectra/Por®. The skilled person is aware of the appropriate tubing cut off size for different purposes. Alternatively, the dialysing step (e) may be carried out in a dialysis device or dialyzer. Suitable dialyzers may be the Slide-A-LyzerTM, the Float-A-Lyzer, the Pur-A-lyzer, the D-Tube, and GeBAflex Dialyzers product lines. [062] The method of the first aspect may further comprise step (f), the step of isolating the medium molecular weight heparin from the dialysed heparin sample.
  • the medium molecular weight heparin may be isolated from the dialysed heparin sample by freeze-drying, centrifuging, or filtration.
  • the medium molecular weight heparin is isolated from the dialysed heparin sample by freeze-drying.
  • Freeze drying is a drying process carried out at low temperature. Freeze drying generally involves reducing temperature and pressure to below the substance's triple point and removing the frozen solvent (e.g. water ice) by sublimation. For aqueous compositions, such as those disclosed herein, freeze drying may be carried out at temperatures of from about -20 °C to about -80 °C, preferably about -40 °C, and pressures of from about 1000 Pa (0.01 bar) to about 10 Pa (0.0001 bar).
  • freeze drying may be carried out at temperatures of from about -20 °C to about -80 °C, preferably about -40 °C, and pressures of from about 1000 Pa (0.01 bar) to about 10 Pa (0.0001 bar).
  • the MMWH may be purified by any suitable method known to the skilled person.
  • the method may further comprise step (g), the step of purifying the medium molecular weight heparin.
  • the method may include an alkaline elimination step.
  • the method may not include an alkaline elimination step.
  • Alkaline elimination may be carried out using an alkali salt such as, for example, sodium hydroxide, potassium hydroxide or lithium hydroxide.
  • the alkaline elimination step may be carried out by addition of an alkali salt to increase the pH of the medium molecular weight heparin solution to about pH 10 to about pH 14, preferably about pH 12, for about 10 minutes to about 3 hours, preferably about 30 minutes, at about room temperature.
  • the method does not include an alkaline elimination step.
  • the method does not include the addition of an alkali metal salt, for example an alkali metal salt such as NaOH, KOH or LiOH.
  • the method does not include the addition of NaOH, KOH or LiOH.
  • a method that does not include an alkaline elimination step or the addition of an alkali metal salt produces medium molecular weight heparin as defined herein that displays very low activity against Factor Ila and/or Xa as compared to UF heparin and low molecular weight heparin.
  • MMWH may be characterised by NMR, disaccharide analysis, ristocetin-induced platelet aggregation (RIPA), Factor X analysis.
  • This method is suitable for preparing medium molecular weight heparin on the milligram, gram or kilogram scale.
  • the method of the first aspect provides medium molecular weight heparin reliably, in good purity, and with reduced degradation.
  • the method may include the further step (h) comprising incubating the medium molecular weight heparin with a reducing agent to produce reduced medium molecular weight heparin (MMMWH-Red).
  • the reducing agent is a mild reducing agent.
  • the reducing agent may be sodium borohydride (NaBF ), sodium cyanoborohydride (NaBHsCN), sodium triacetoxyborohydride (NaBHfOAcJs) or potassium borohydride (KBH4).
  • step (h) is carried out at between about 10 °C and about 30 °C, or between about 15 °C and about 25 °C, or between about 20 °C and about 25 °C.
  • step (f) is carried out at about 25 °C.
  • step (f) is carried out for from about 1 hour to about 24 hours, more preferably from about 2 hours to about 16 hours, more preferably from about 3 hours to about 12 hours, more preferably from about 6 hours to about 10 hours.
  • the solvent for step (h) may typically be selected from the group consisting of methanol, ethanol, water, THF, or combinations thereof.
  • the solvent in step (h) is water.
  • the method of synthesis of medium molecular weight heparin may consist of or consist essentially of the steps: (a) dissolving unfractionated heparin in an aqueous buffer solution adjusted to between about pH 5.0 and about pH 9.0 to provide a first solution; (b) adding an oxidising agent to the first solution to provide a second solution; (c) incubating the second solution at a temperature of from about 0 °C to about 10 °C to form a medium molecular weight heparin solution; and (d) purifying the medium molecular weight heparin.
  • the method of synthesis of medium molecular weight heparin may consist of or consist essentially of the steps: (a) dissolving unfractionated heparin in an aqueous buffer solution adjusted to between about pH 5.0 and about pH 9.0 to provide a first solution; (b) adding an oxidising agent to the first solution to provide a second solution; (c) incubating the second solution at a temperature of from about 0 °C to about 10 °C to form a medium molecular weight heparin solution; (d) inactivating the oxidising agent in the medium molecular weight heparin solution; and (e) purifying the medium molecular weight heparin.
  • the method of synthesis of medium molecular weight heparin may consist of or consist essentially of the steps: (a) dissolving unfractionated heparin in an aqueous buffer solution adjusted to between about pH 5.0 and about pH 9.0 to provide a first solution; (b) adding an oxidising agent to the first solution to provide a second solution; (c) incubating the second solution at a temperature of from about 0 °C to about 10 °C to form a medium molecular weight heparin solution; (d) inactivating the oxidising agent in the medium molecular weight heparin solution; and (e) dialysing the medium molecular weight heparin solution in a dialysate to provide a dialysed medium molecular weight heparin sample.
  • the method of synthesis of medium molecular weight heparin may consist of or consist essentially of the steps: (a) dissolving unfractionated heparin in an aqueous buffer solution adjusted to between about pH 5.0 and about pH 9.0 to provide a first solution; (b) adding an oxidising agent to the first solution to provide a second solution; (c) incubating the second solution at a temperature of from about 0 °C to about 10 °C to form a medium molecular weight heparin solution; (d) inactivating the oxidising agent in the medium molecular weight heparin solution; (e) dialysing the medium molecular weight heparin solution in a dialysate to provide a dialysed medium molecular weight heparin sample; and (f) Isolating the medium molecular weight heparin from the dialysed heparin sample.
  • the invention provides a kit suitable for preparing medium molecular weight heparin, wherein the kit comprises (a) unfractionated heparin; (b) an aqueous buffer solution adjusted to between about pH 5.0 and about pH 9.0; (c) an oxidising agent; and (d) optionally, an inactivating agent.
  • MMWH produced by the method of the first aspect of the invention includes two aldehyde groups on the glucuronic acid.
  • the reactivity of the aldehyde groups may result in reaction of the aldehyde groups with amine residues on proteins within the body via a Schiff base reaction.
  • the invention provides a method of preparing reduced medium molecular weight heparin (MMWH-Red).
  • MMWH-Red does not comprise aldehyde groups, or comprises fewer aldehyde groups than MMWH.
  • the method of the third aspect comprises the following steps: (a) dissolving unfractionated (UF) heparin in an aqueous buffer solution adjusted to between about pH 5.0 and about pH 9.0 to provide a first solution; (b) adding an oxidising agent to the first solution to provide a second solution; (c) incubating the second solution at a temperature of from about 0 °C to about 10 °C to form a medium molecular weight heparin solution; and (d) incubating the medium molecular weight heparin with a reducing agent to produce reduced medium molecular weight heparin (MMWH-Red).
  • the reduced medium molecular weight heparin prepared by the method of the third aspect of the invention may comprise polysaccharide chains with an average molecular mass in the range of about 8000 Da (g/mol) to about 13 000 Da (g/mol), preferably about 10 000 Da (g/mol) to about 12 000 Da (g/mol).
  • the reduced medium molecular weight heparin prepared by the method of the third aspect of the invention may comprise polysaccharide chains with an average molecular mass of about 11 000 Da (g/mol).
  • the molecular weight of the MMWH-Red prepared by the method of the third aspect of the invention may be determined by size exclusion chromatography as described herein.
  • the MMWH-Red prepared by the method of the third aspect may comprise at least three units of a GlcNS6S-ldoA2S (or ldoA2S-GlcNS6S) disaccharide.
  • the GlcNS6S and ldoA2S monosaccharides are linked by an al-4 linkage between GlcNS6S and ldoA2S, i.e. GlcNS6Sal-4ldoA2S.
  • the MMWH-Red prepared by the method of the third aspect may comprise at least four units, preferably at least five units, preferably at least six units, preferably at least eight units, preferably at least ten units of a GlcNS6S-ldoA2S disaccharide.
  • the MMWH-Red prepared by the method of the third aspect may comprise less than or equal to 25 units of the GlcNS6S-ldoA2S disaccharide, for example less than or equal to 20 units.
  • the presence of the units of the GlcNS6S-ldoA2S disaccharide may be determined by an antibody, mass spectrometry, or inferred from chemical and enzymatical studies.
  • the GlcNS6S- ldoA2S units may be ordered in succession.
  • the MMWH-Red prepared by the method of the first aspect may comprise UA2S-GlcNS6S, UA2S-GlcNS, UA-GIcNAc, wherein U may be iduronic acid (IdoA) or glucuronic acid (GlcA).
  • the medium molecular weight heparin prepared by the method of the third aspect may comprise at least about 60% UA2S-GlcNS6S, UA2S-GlcNS, and UA-GIcNAc.
  • the MMWH-Red prepared by the method of the third aspect may comprise at least about 45%, preferably at least about 48%, preferably at least about 49%, preferably at least about 60% UA2S-GlcNS6S.
  • the MMWH-Red prepared by the method of the third aspect may comprise up to about 60%, preferably up to about 70%, preferably up to about 85% UA2S-GlcNS6S.
  • the MMWH-Red prepared by the method of the third aspect may comprise at least about 4%, preferably at least about 5%, preferably at least about 6%, preferably at least about 10% UA2S-GlcNS.
  • the MMWH-Red prepared by the method of the third aspect may comprise up to about 15%, preferably up to about 20% UA2S-GlcNS.
  • the MMWH-Red prepared by the method of the third aspect may comprise at least 4%, preferably at least 5%, preferably at least 6%, preferably at least about 10% UA-GIcNAc.
  • the MMWH-Red prepared by the method of the third aspect may comprise up to about 15%, preferably up to about 20% UA-GIcNAc. In some embodiments the MMWH-Red prepared by the method of the third aspect may comprise at least 49.2% UA2S-GlcNS6S, 5.4% UA2S- GlcN and 5.4% UA-GIcNAc. In some embodiments the MMWH-Red prepared by the method of the third aspect may comprise at least 82% UA2S-GlcNS6S, 9% UA2S-GlcNS and 9% UA-GIcNAc. The percentage composition of UA-GIcNAc comprised in the MMWH-Red may be enriched compared to unfractionated heparin.
  • the reducing agent may be sodium borohydride (NaBH4), sodium cyanoborohydride, sodium triacetoxyborohydride or potassium borohydride (KBH4).
  • the reducing agent is sodium borohydride.
  • the reducing agent is used at greater than about 0.5 molar equivalents, or greater than about 1 molar equivalent, or greater than about 2 molar equivalents, or greater than about 3 molar equivalents, or greater than about 5 molar equivalents relative to medium molecular weight heparin.
  • the reducing agent is used at less than about 15 molar equivalents, or less than about 12 molar equivalents, or less than about 10 molar equivalents, or less than about 8 molar equivalents, or less than about 6 molar equivalents, or less than about 5 molar equivalents relative to medium molecular weight heparin.
  • the reducing agent may be used in amount of between about 0.5 molar equivalents and about 15 molar equivalents, or between about 1 molar equivalents and about 10 molar equivalents, or between about 2 molar equivalents and about 6 molar equivalents.
  • step (d) is carried out at between about 0 °C and about 30 °C, or between about 5 °C and about 25 °C, or between about 10 °C and about 20 °C. Preferably, step(d) is carried out at about 25 °C. Typically, step (d) is carried out for from about 1 hour to about 24 hours, more preferably from about 2 hours to about 16 hours, more preferably from about 3 hours to about 12 hours, more preferably from about 6 hours to about 10 hours.
  • the solvent for step (d) may typically be selected from the group consisting of methanol, ethanol, water, THF, dichloroethane, or combinations thereof. Preferably, the solvent in step (d) is water.
  • the method of the first aspect may further comprise the step of inactivating the oxidising agent in the MMWH-Red solution.
  • the oxidising agent may be inactivated by the addition of an inactivating agent selected from the group consisting of: D-mannitol, glycerol, /V-acetylmethionine, sodium sulfite, and combinations thereof.
  • an inactivating agent selected from the group consisting of: D-mannitol, glycerol, /V-acetylmethionine, sodium sulfite, and combinations thereof.
  • a particularly preferred inactivating agent is D-mannitol.
  • the molar ratio of the oxidising agent to the inactivating agent may be from about 1:1 to about 1:10, more preferably from about 1:2 to about 1:8, more preferably from about 1:3 to about 1:6, more preferably from about 1:4 to about 1:5. Typically, the molar ratio of the oxidising agent to the inactivating agent may be about 1:2 or about 1:4.
  • the MMWH-Red may be purified by any suitable method known to the skilled person.
  • the method may further comprise the step of purifying the medium molecular weight heparin.
  • the method may further comprise dialysing the medium molecular weight heparin solution in a dialysate to provide a dialysed medium molecular weight heparin sample prior to the reducing step.
  • This method is suitable for preparing reduced medium molecular weight heparin on the milligram, gram or kilogram scale.
  • the method of the third aspect provides reduced medium molecular weight heparin reliably, in good purity, and with reduced degradation.
  • the method of synthesis of reduced medium molecular weight heparin may consist of or consist essentially of the steps: (a) dissolving unfractionated (UF) heparin in an aqueous buffer solution adjusted to between about pH 5.0 and about pH 9.0 to provide a first solution; (b) adding an oxidising agent to the first solution to provide a second solution; (c) incubating the second solution at a temperature of from about 0 °C to about 10 °C to form a medium molecular weight heparin solution; (d) incubating the medium molecular weight heparin with a reducing agent to produce reduced medium molecular weight heparin (MMWH-Red); and (e) purifying the MMWH-Red.
  • the method of synthesis of reduced medium molecular weight heparin may consist of or consist essentially of the steps: (a) dissolving unfractionated heparin in an aqueous buffer solution adjusted to between about pH 5.0 and about pH 9.0 to provide a first solution; (b) adding an oxidising agent to the first solution to provide a second solution; (c) incubating the second solution at a temperature of from about 0 °C to about 10 °C to form a medium molecular weight heparin solution; (d) inactivating the oxidising agent in the medium molecular weight heparin solution; (e) incubating the medium molecular weight heparin with a reducing agent to produce reduced medium molecular weight heparin (MMWH-Red); and (f) purifying the MMWH-Red.
  • the method of synthesis of reduced medium molecular weight heparin may consist of or consist essentially of the steps: (a) dissolving unfractionated heparin in an aqueous buffer solution adjusted to between about pH 5.0 and about pH 9.0 to provide a first solution; (b) adding an oxidising agent to the first solution to provide a second solution; (c) incubating the second solution at a temperature of from about 0 °C to about 10 °C to form a medium molecular weight heparin solution; (d) inactivating the oxidising agent in the medium molecular weight heparin solution; (e) dialysing the medium molecular weight heparin solution in a dialysate to provide a dialysed medium molecular weight heparin sample; (f) incubating the dialysed medium molecular weight heparin with a reducing agent to produce reduced medium molecular weight heparin (MMWH-Red); and (g) purifying the MMWH-
  • the method of synthesis of reduced medium molecular weight heparin may consist of or consist essentially of the steps: (a) dissolving unfractionated heparin in an aqueous buffer solution adjusted to between about pH 5.0 and about pH 9.0 to provide a first solution; (b) adding an oxidising agent to the first solution to provide a second solution; (c) incubating the second solution at a temperature of from about 0 °C to about 10 °C to form a medium molecular weight heparin solution; (d) inactivating the oxidising agent in the medium molecular weight heparin solution; (e) dialysing the medium molecular weight heparin solution in a dialysate to provide a dialysed medium molecular weight heparin sample; (f) Isolating the medium molecular weight heparin from the dialysed heparin sample; (g) incubating the medium molecular weight heparin with a reducing agent to produce reduced medium mole
  • the reducing agent is a mild reducing agent.
  • the mild reducing agent may selectively reduce aldehydes and ketones to alcohols in the presence of esters. In other words, the mild reducing agent reduces aldehydes and ketones to alcohols at a faster rate than it reduces esters to alcohols.
  • the mild reducing agent does not reduce carboxylic acids, nitriles, and amides under normal conditions.
  • the mild reducing agent may be sodium borohydride (NaBF ).
  • the method does not include an alkaline elimination step.
  • the method does not include the addition of an alkali metal salt, for example an alkali metal salt such as NaOH, KOH or LiOH.
  • the method does not include the addition of NaOH, KOH or LiOH.
  • a method that does not include an alkaline elimination step or the addition of an alkali metal salt produces MMWH-Red as defined herein that displays very low activity against Factor Ila and/or Xa as compared to UF heparin and low molecular weight heparin.
  • MMWH and MMWH-Red inhibit von Willebrand Factor, and so are appropriate active pharmaceutical ingredients (APIs) and drug products for the purposes of the invention.
  • APIs active pharmaceutical ingredients
  • MMWH-Red may display greater stability as an API and drug product compared to MMWH. Furthermore, MMWH-Red may reduce the potential for side reaction with excipients comprised in the drug product and MMWH-Red may reduce interactions with proteins in vivo.
  • the invention provides reduced medium molecular weight heparin (MMWH-Red).
  • MMWH-Red may be prepared according to the first or third aspect of the invention.
  • MMWH-Red does not comprise an aldehyde or comprises fewer aldehydes than MMWH produced according to the first aspect.
  • the presence of an aldehyde or lack thereof may be determined using 2,4-Dinitrophenyl Hydrazine test.
  • MMWH-Red may not produce an orange-yellow precipitate with reacted with 2,4-dinitrophenylhydrazine or less orange-yellow precipitate than a corresponding amount of starting material.
  • the reduction of MMWH to MMWH-Red may be monitored by infra-red spectroscopy.
  • MMWH-Red may be characterised by NMR, disaccharide analysis, ristocetin-induced platelet aggregation (RIPA), Factor X analysis.
  • the invention provides MMWH-Red produced according to the following steps:
  • the invention provides a composition comprising MMWH-Red.
  • the composition is a pharmaceutical composition.
  • endotheliopathy may be associated with a number of diseases.
  • MMWH- Red inhibits von Willebrand factor.
  • the Inventor has found that MMWH-Red can be used to treat endotheliopathy, particularly endotheliopathy in a patient having a high plasma von Willebrand factor level.
  • endotheliopathy may be caused by a large number of diseases and/or conditions as described herein, endotheliopathy with reference to COVID-19 or SARS-CoV-2 will primarily be discussed herein. The skilled person will understand that this discussion is merely to provide an example and should not be considered limiting on the present invention.
  • ARDS is often associated with sepsis from a variety of different causes and has been seen in severe acute respiratory syndrome (SARS) due to SARS-CoV (16), Middle East respiratory syndrome (MERS) due to MERS-CoV (17) and now COVID-19.
  • SARS severe acute respiratory syndrome
  • MERS Middle East respiratory syndrome
  • Sepsis-associated ARDS often develops with other organ dysfunction such as encephalopathy (18), hepatic failure (19)(20), acute renal failure, and acute necrotizing pancreatitis (21). This multi-organ involvement suggests ARDS may not be the primary disease but is part of an on-going systemic pathogenic mechanism triggered by an infection or another critical illness.
  • EA-VMTD endotheliopathy associated VMTD
  • DIMT disseminated microthrombosis
  • VWF Von Willebrand Factor
  • VWF The vast majority of VWF found in the plasma is derived from the VWF synthesised within the ECs, where it is stored within the Weibel Palade Bodies (WPB). Although restricted to ECs there are differences in the synthesis of VWF within the different vascular beds of the body, with the small vessels of the lung and brain expressing higher levels of VWF than similar sized vessels of the liver or kidney and higher levels in venous rather than arterial ECs (37). A major portion of the VWF stored in the WPBs of endothelial cells is made up of ultra-large VWF (ULVWF). These ultra-large VWF multimers are more adhesive than the smaller VWF multimers in the circulation (38). Upon secretion, ULVWF can spontaneously bind platelets.
  • ULVWF ultra-large VWF
  • Inflammatory cytokines such as lnterleukin-1 and tumour necrosis factor (TNF)-alpha can trigger the exocytosis of WPBs with release of their contents.
  • TNF tumour necrosis factor
  • plasma level of VWF can be used as a marker of endothelial activation and vascular inflammation and raised levels of VWF have been shown to associate with ARDS and sepsis, and to correlate independently to mortality (39,40).
  • the secreted VWF which partly enters the circulation and partly binds to the endothelium, is sensitive to shear stress. This shear stress unfolds the VWF and exposes sites for platelet binding, self-association as well as for cleavage via the enzyme ADAMTS13. It has previously been shown these VWF molecules can self-associate into long 'strings' in the direction of flow, both arterial and venous, that bind to platelets and are adherent to the endothelium (41-43). A protease, ADAMTS13, cleaves VWF and ULVWF, perfusion of which over these platelet-VWF strings led to them being rapidly removed from the circulation (41).
  • the ULVWF multimers released from the WPBs have a lower shear stress for unfolding and therefore may represent the initiating molecules for this self-assembly process which leads to hyper-adhesive strings capturing platelets.
  • the binding of platelets to the VWF occurs via the GP lb receptor.
  • the binding site for this receptor is usually not exposed when the VWF is in its globular form and therefore cannot bind to platelets. Once VWF unfurls, secondary to shear stress, the binding site is exposed and binds with high affinity to platelets.
  • the binding of platelets to VWF may cause a conformational change leading to activation of the integrin G PH bl I la (also known as a2b
  • the use of standard anti-platelet agents is likely to be ineffective (Aspirin or P2Y12 inhibitors) or only partially effective in mitigating this pathological process as was suggested by the cohort study of Tremblay et al (44).
  • This ability to form VWF-platelet rich thrombi in the microvasculature is the hallmark of acquired thrombotic thrombocytopaenic purpura (TTP) in which auto-antibodies to ADAMTS13 are present.
  • IL-6 can inhibit the cleavage of ULVWF - platelet strings (45).
  • IL-6 can inhibit the cleavage of ULVWF - platelet strings (45).
  • ADAMTS13 a variety of cytokines including IL-6 and TNF-alpha (46).
  • IL-6 IL-6
  • TNF-alpha TNF-alpha
  • VWF:Ag von Willebrand Factor antigen
  • Heparin is a naturally occurring, highly sulphated polysaccharide characterised by a wide molecular weight range of polysaccharide chains. Heparin acts at a variety of different ligands with varied actions. Heparin is a member of the glycosaminoglycan carbohydrate family and consists of repeating disaccharide units of GlcApi-4GlcNAcal-4 with poly-disperse sulfation, N-acetylation and uronosyl epimerization. Heparin is highly heterogenous. Heparin may be isolated from natural sources, such as porcine intestine or bovine lung.
  • Heparin isolated from natural sources contains polysaccharide chains with molecular weights ranging from about 3000 Da to about 30,000 Da. This is known as unfractionated heparin (UFH).
  • UHF unfractionated heparin
  • UFH can be enzymatically or chemically treated to deliver shorter polysaccharide chains.
  • Heparinase I cleaves at the a-1,4 linkage between nonacetylated GlcNS6S and ldoA2S.
  • Periodate treatment of UFH followed by alkaline elimination cleaves the polysaccharide chain at unsulfated uronic acid units.
  • the products of the chemically or enzymatically treated UFH can be affinity purified to yield fractionated heparin where the molecular weight of the polysaccharides in each fraction can be readily determined.
  • Low molecular weight heparin (LMWH) contains polysaccharide chains in the range of about 4000 Da to about 8000 Da.
  • Medium molecular weight heparins with specific disaccharide units can be produced from unfractionated heparins. These medium molecular weight heparins may have specificity towards inhibiting VWF-GPIb binding, hence stopping microthrombosis, but as they have little effect on anti-thrombin III they have little anti-coagulant effect. Thus, medium molecular weight heparins with a mass of about 11 000 Da (g/mol) may represent an ideal treatment option when considering the treatment of patients with pro-thrombotic states that are dependent upon increased VWF levels and endotheliopathies.
  • MMWH MMWH.
  • the result is a significant reduction in the activity as performed by the anti-Xa and anti-lla tests routinely performed on heparin. It is proposed that this oxidation of the glucuronic acid changes the binding capability of heparin to antithrombin III (ATI 11).
  • ATI 11 antithrombin III
  • the ristocetin-induced platelet aggregation (RIPA) test shows an increased activity of the MMWH. This indicates that the von Willebrand factor interaction of the heparin polysaccharide remains intact and possibly enhanced.
  • the two aldehyde groups on the glucuronic acid may in some circumstances be reactive. This reactivity can potentially decrease the stability of the oxidized polysaccharide over time. Additionally, it may interact with free amines on proteins when injected into the body. The latter would be through a Schiff base reaction with the free amines in the same way as glucose reacts with hemoglobin to form the well known glycated hemoglobin commonly known as A1C.
  • A1C glycated hemoglobin
  • One potential solution would be to reduce the aldehyde functionalities to alcohol functionalities. The could be easily performed by a mild reducing agent such as sodium borohydride (NaBH 4 ).
  • MMWH-Red maintains von Willebrand activity of MMWH, greater stability as an active pharmaceutical ingredient (API) and drug product, minimal interaction with pharmaceutical excipients, reduced or no reaction with proteins in vivo, minimising side effects.
  • API active pharmaceutical ingredient
  • the invention provides MMWH-Red according to the fourth or fifth aspect of the invention or a composition according to the sixth aspect of the invention for use in the treatment of endotheliopathy.
  • the MMWH-Red may inhibit von Willebrand factor (VWF).
  • VWF von Willebrand factor
  • the MMWH-Red may inhibit multimers of VWF, preferably ultra-large VWF.
  • the MMWH-Red may inhibit the binding of platelets to VWF.
  • the invention provides MMWH-Red or a composition comprising MMWH-Red for use in the treatment of endotheliopathy.
  • the invention provides MMWH-Red or a composition comprising MMWH-Red for use in the treatment of endotheliopathy in a patient having a plasma von Willebrand factor antigen to ADAMTS13 ratio of at least about 2.
  • the invention provides MMWH-Red or a composition comprising MMWH-Red for use in the treatment of endotheliopathy in a patient having a plasma von Willebrand factor to ADAMTS13 ratio of at least about 2.
  • the patient may have a VWF:ADAMTS13 ratio of at least about 2, of at least about 4, of at least about 8, or of at least about 10.
  • the patient may have a VWF:ADAMTS13 ratio greater than about 2, greater than about 4, or greater than about 8, or greater than about 10.
  • the patient may have a VWF:ADAMTS13 ratio of about 2-16, about 4-12, or preferably about 6-10.
  • a patient having a VWF to ADAMTS13 ratio of greater than about 8 typically indicates severe illness and often is indicative of a patient deteriorating towards death.
  • the patient may have a VWF antigen:ADAMTS13 ratio of at least about 2, of at least about 4, of at least about 8, or of at least about 10.
  • the patient may have a VWF antigen:ADAMTS13 ratio greater than about 2, greater than about 4, or greater than about 8, or greater than about 10.
  • the patient may have a VWF antigen:ADAMTS13 ratio of about 2-16, about 4-12, or preferably about 6- 10.
  • a patient having a VWF antigen to ADAMTS13 ratio of greater than about 8 typically indicates severe illness and often is indicative of a patient deteriorating towards death.
  • the level of VWF and ADAMTS13 in the patient may be measured using an ELISA.
  • the ratio may be calculated as described by Huisman et al (Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS-CoV-2. Int J Lab Hematol. 2020 Oct;42(5):e211-2). Briefly, the level of the VWF antigen may be determined in international units and the level of ADAMTS13 may be determined in international units and then the ratio of VWF antigen: ADAMTS13 determined. [006] Normal levels of plasma VWF are in the range of from about 50 III per dL to about 200 III per dL.
  • the mean level of plasma VWF in the general population is about 100 III per dL.
  • High levels of plasma VWF are those of about 200 III per dL or more, for example from about 200 IU per dL to about 400 IU per dL, from about 225 IU per dL to about 375 IU per dL, from about 250 IU per dL to about 350 IU per dL, from about 275 IU per dL to about 300 IU per dL.
  • the patient may have a raised VWF antigen level of about 150% or more, of about 175% or more, of about 200% or more, of about 300% or more, of about 350% or more, or about 400% or more, or of about 500% or more.
  • the patient may have a VWF antigen level of up to about 600%, up to about 700%, up to about 800%, or up to about 1000%.
  • levels of plasma VWF may be temporarily raised by infections, inflammation, trauma, and with physical and emotional stressors.
  • the patient may have a non- temporarily raised plasma von Willebrand factor level, for example for at least about six hours, at least about 12 hours, at least about 18 hours or at least about 24 hours.
  • the patient may have a raised plasma von Willebrand factor level for at least about one day, at least about two days, at least about three days, at least about four days, at least about five days, at least about six days, or at least about seven days.
  • the patient may have a raised plasma von Willebrand factor level for at least about one week, at least about two weeks, at least about three weeks or at least about four weeks.
  • the patient may have a raised plasma von Willebrand factor level for at least about one month, at least about two months, at least about three months, at least about four months, at least about five months, at least about six months or at least about one year.
  • the patient may have a raised plasma von Willebrand factor level for up to about one week, up to about four weeks, up to about two months, up to about four months, up to about six months, or up to about one year.
  • the MMWH-Red may have a mass of about 11 000 Da (g/mol).
  • the reduced medium molecular weight heparin may comprise at least three units of the GlcNS6S-ldoA2S (or ldoA2S- GlcNS6S) disaccharide.
  • the endotheliopathy may be caused by any disease.
  • the endotheliopathy may be caused by COVID-19, infection, viral infection, acute respiratory distress syndrome (ARDS), cancer, bacterial infection, septicaemia, sepsis, cardiovascular disease, diabetes mellitus, trauma, in particular brain or head trauma, burns, inhalational injury, drugs and drug reactions, haematological conditions, subarachnoid haemorrhage, aneurysmal diseases, stroke, or brain parenchymal haemorrhage.
  • ARDS acute respiratory distress syndrome
  • cancer bacterial infection
  • septicaemia septicaemia
  • sepsis sepsis
  • cardiovascular disease diabetes mellitus
  • trauma in particular brain or head trauma
  • burns inhalational injury
  • drugs and drug reactions haematological conditions
  • subarachnoid haemorrhage aneurysmal diseases
  • stroke or brain parenchymal haemorrhage.
  • the endotheliopathy may be caused by
  • the endotheliopathy may be caused by cancer, in particular leukaemia, lymphoma, myeloma, or a solid organ cancer, such as colon cancer, breast cancer, brain cancer, lung cancer, pancreatic cancer, testicular cancer, prostate cancer, cervical cancer, liver cancer, or skin cancer.
  • cancer in particular leukaemia, lymphoma, myeloma, or a solid organ cancer, such as colon cancer, breast cancer, brain cancer, lung cancer, pancreatic cancer, testicular cancer, prostate cancer, cervical cancer, liver cancer, or skin cancer.
  • the infection may be bacterial, fungal, or parasitic.
  • the infection may be bacterial.
  • the bacterial infection may be Actinomyces israelii, Bacillus anthracis, Bacteroides fragilis, Bordetella pertussis, Borrelia burgdoferi, Borrelia garinii, Borrelia afzelaii, Borrelia recurrentis, Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis, Campylobacter jejuni, Chlamydia pneumoniae, Chlamydia trachomatis, Chlamydophilia psittaci, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, Corynebacterium diphtheriae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Francis
  • the infection may be fungal.
  • the fungal infection may be Aspergillus, Blastomyces, Candida, Coccidioides, Cryptococcus neoformans, Cryptococcus gattii, Histoplasma, mucormycetes, Tinea cruris, Tinea corporis, or Tinea pedis.
  • the infection may be parasitic.
  • the parasitic infection may be protozoan eye infection, Chagas' disease, leishmaniasis, toxoplasmosis, giardiasis, malaria, microsporidiosis, or Rhinosporidiosis.
  • the parasitic infection is malaria.
  • the viral infection may be SARS-CoV-2.
  • SARS-CoV-2 is the virus responsible for the disease COVID-19. COVID-19 can result in ARDS.
  • the endotheliopathy may be caused by SARS-CoV-2 infection.
  • the endotheliopathy may be caused by COVID-19.
  • the endotheliopathy may be caused by ARDS.
  • the endotheliopathy may be caused by cancer.
  • the cancer may be leukaemia, lymphoma or myeloma.
  • the cancer may be solid organ cancer, for example colon cancer, breast cancer, brain cancer, lung cancer, pancreatic cancer, testicular cancer, prostate cancer, cervical cancer, liver cancer, or skin cancer.
  • the endotheliopathy may be caused by haematological conditions, for example Thrombotic thrombocytopenic purpura, anaemia, or sickle cell disease.
  • Dysfunctional endothelial cells may allow for the passage of tumour cells circulating in the blood to pass into the tissues.
  • treating the endotheliopathy may prevent the haematogenous spread of blood borne cancers.
  • the treatment of the endotheliopathy may inhibit the haematogenous spread of cancer.
  • the medium molecular weight heparin may inhibit the haematogenous spread of cancer.
  • Biomarkers of endotheliopathy may include raised von Willebrand factor (VWF) levels, ultralarge von Willebrand factor (ULVWF) levels, Factor VIII levels as well as other markers such as Syndecan 1, VWF antigen, VWF activity, VWF multimers, ADAMTS13 levels, platelet counts, VCAM-1, ICAM-1, P-selectin levels, VWF:ADAMTS13 ratio or VWF antigen:ADAMTS13 ratio.
  • VWF von Willebrand factor
  • UUVWF ultralarge von Willebrand factor
  • Factor VIII levels as well as other markers such as Syndecan 1, VWF antigen, VWF activity, VWF multimers, ADAMTS13 levels, platelet counts, VCAM-1, ICAM-1, P-selectin levels, VWF:ADAMTS13 ratio or VWF antigen:ADAMTS13 ratio.
  • a biomarker of endotheliopathy is the ratio of VWF:ADAMTS13 or VWF antigen: ADAMTS13.
  • the patient may have raised plasma von Willebrand factor (VWF) levels compared to a healthy control subject.
  • the patient may have sustained high levels of plasma VWF compared to a healthy control.
  • the levels of plasma VWF may be raised compared to a healthy control subject over a period of at least about one day, at least about two days, at least about three days, at least about four days, at least about five days, at least about six days, or preferably at least about one week.
  • the levels of plasma VWF may be raised compared to a healthy control subject for a period of up to about one week, up to about four weeks, up to about two months, up to about four months, up to about six months, or up to about one year.
  • the level of plasma VWF may be raised to at least about 50 nmol/L, preferably at least about 60 nmol/L, even more preferably at least about 70 nmol/L or yet even more preferably at least about 90 nmol/L.
  • the level of plasma VWF may be raised to about 130 nmol/L, to about 150 nmol/L, or to about 200 nmol/L.
  • the level of plasma VWF may be raised to at least about 50 nmol/L for at least about one day, at least about two days, at least about three days, at least about four days, at least about five days, at least about six days, at least about one week, at least about one month or at least about one year.
  • the level of plasma VWF may be raised to at least about 60 nmol/L for at least about one day, at least about two days, at least about three, days, at least about four days, at least about five days, at least about six days, at least about one week, at least about one month or at least about one year.
  • the level of plasma VWF may be raised to at least about 70 nmol/L for at least about one day, at least about two days, at least about three days, at least about four days, at least about five days, at least about six days, at least about one week, at least about one month or at least about one year.
  • the level of plasma VWF may be raised to at least about 90 nmol/L for at least about one day, at least about two days, at least about three days, at least about four days, at least about five days, at least about six days, at least about one week, at least about one month or at least about one year.
  • the plasma VWF level may be measured using an Enzyme-Linked Immunosorbent Assay (ELISA).
  • the patient may have a plasma von Willebrand factor level of about 200 IU pr dL or more for at least about six hours, at least about 12 hours, at least about 18 hours or at least about 24 hours.
  • the patient may have a plasma von Willebrand factor level of about 200 IU pr dL or more for at least about one day, at least about two days, at least about three days, at least about four days, at least about five days, at least about six days, or at least about seven days.
  • the patient may have a plasma von Willebrand factor level of about 200 IU pr dL or more for at least about one week, at least about two weeks, at least about three weeks or at least about four weeks.
  • the patient may have a plasma von Willebrand factor level of about 200 IU pr dL or more for at least about one month, at least about two months, at least about three months, at least about four months, at least about five months, at least about six months or at least about one year.
  • Vascular endothelial function can be assessed in the coronary and peripheral circulations.
  • Non-invasive tests for the assessment of coronary endothelial function include Doppler echocardiography where blood flow is measured in response to pharmacological or physiological stimuli.
  • Other tests include positron emission tomography and phase-contrast magnetic resonance imaging.
  • the gold standard test involves invasive quantitative coronary angiography to examine changes in diameter in response to intracoronary infusions of endothelium-dependent vasodilators such as acetylcholine.
  • Assessment of the endothelium in the peripheral circulation includes brachial artery ultrasound and strain-gauge venous impedance plethysmography.
  • Binding of MMWH-Red to VWF may be assessed by a competitive binding assay.
  • Heparin- Sepharose beads may be incubated with labelled VWF, for example 125 l-vWF, for a period of time to allow the labelled VWF to bind to the immobilized heparin. Varying concentrations of the MMWH-Red may then be added and the amount of displaced labelled VWF determined.
  • Other methods to determine MMWH-Red binding to VWF may include surface plasmon resonance, biolayer interferometry, isothermal titration calorimetry, fluorescence polarisation binding assays, ELISA and microscale thermophoresis.
  • the inhibition of platelets binding to VWF may be assessed by ristocetin-induced agglutination of fixed platelets. Platelets may be incubated with the medium molecular weight heparin and citrate treated plasma (a VWF source). Ristocetin may then be added, and platelet agglutination then determined. The MMWH may fully inhibit VWF-induced platelet aggregation at a concentration of 15 pM when measured by a ristocetin-induced platelet aggregation assay. Other methods to determine the inhibition of VWF binding to platelets may include ELISA, fluorescence assisted cell sorting, dynamic light scattering, or flow chamber assays.
  • the MMWH-Red may have a mass in the range of greater than about 8000 Da (g/mol) to about 13 000 Da (g/mol), preferably about 10 000 Da (g/mol) to about 12 000 Da (g/mol).
  • the MMWH-Red may have a mass of about 11 000 Da (g/mol).
  • the MMWH-Red may comprise polysaccharide chains with an average molecular mass in the range of about 9000 Da (g/mol) to about 13 000 Da (g/mol), preferably about 10 000 Da (g/mol) to about 12 000 Da (g/mol).
  • the MMWH-Red may comprise polysaccharide chains with an average molecular mass of about 11 000 Da (g/mol).
  • the molecular weight of the MMWH-Red may be determined by mass spectrometry or size exclusion chromatography, for example.
  • the MMWH-Red may comprise at least three units of a GlcNS6S-ldoA2S disaccharide, for example at least four units, at least five units, at least six units, at least eight units, or at least ten units.
  • the medium molecular weight heparin may comprise less than or equal to 25 units of the GlcNS6S- ldoA2S disaccharide, for example less than or equal to 20 units.
  • the presence of the units of the GlcNS6S-ldoA2S disaccharide may be determined by an antibody, mass spectrometry, or inferred from chemical and enzymatical studies.
  • the GlcNS6S-ldoA2S units may be ordered in succession.
  • the MMWH-Red may comprise at least three units of a ldoA2S-GlcNS6S disaccharide, for example at least four units, at least five units, at least six units, at least eight units, or at least ten units.
  • the reduced medium molecular weight heparin may comprise less than or equal to 25 units of the ldoA2S-GlcNS6S disaccharide, for example less than or equal to 20 units.
  • the presence of the units of the ldoA2S-GlcNS6S disaccharide may be determined by an antibody, mass spectrometry, or inferred from chemical and enzymatical studies.
  • the ldoA2S-GlcNS6S units may be ordered in succession. The number of ldoA2S-GlcNS6S units may be tailored to provide a desired anti-VWF activity and/or standard anticoagulant activity.
  • the MMWH-Red may comprise UA2S-GlcNS6S, UA2S-GlcNS, UA -GIcNAc.
  • the MMWH-Red may comprise at least about 60% UA2S-GlcNS6S, UA2S-GlcNS, and UA-GIcNAc.
  • the MMWH-Red may comprise at least about 45%, preferably at least about 48%, preferably at least about 49%, preferably at least about 60%UA2S-GlcNS6S.
  • the MMWH-Red may comprise up to about 60%, preferably up to about 70%, preferably up to about 85% UA2S-GlcNS6S.
  • the MMWH-Red may comprise at least about 4%, preferably at least about 5%, preferably at least about 6%, preferably at least about 10% UA2S- GIcNS.
  • the MMWH-Red may comprise up to about 15%, preferably up to about 20% UA2S-GlcNS.
  • the MMWH-Red may comprise at least 4%, preferably at least 5%, preferably at least 6%, preferably at least about 10% UA-GIcNAc.
  • the reduced medium molecular weight heparin may comprise up to about 15%, preferably up to about 20% UA-GIcNAc.
  • the MMWH-Red may comprise at least 49.2% UA2S-GlcNS6S, 5.4% UA2S-GlcN and 5.4% UA-GIcNAc. In some embodiments the MMWH-Red may comprise at least 82% UA2S-GlcNS6S, 9% UA2S-GlcNS and 9% UA-GIcNAc. The percentage composition of UA -GIcNAc comprised in the MMWH-Red may be enriched compared to unfractionated heparin.
  • the treatment of endotheliopathy by MMWH-Red may inhibit the haematogenous spread of cancer.
  • Human tumour cells can bind to VWF under shear flow conditions with both melanoma and colon cancer cells demonstrating this ability.
  • the immobilized platelets, bound to the VWF have been shown to mediate tethering, rolling, and the firm adhesion of different cancerous cell lines under flow shear stress.
  • the VWF played a critical role in enabling this firm adhesion of the tumour cells to the immobilized platelets.
  • the existing data suggests that VWF plays an important role in tethering cancerous cells.
  • the VWF-Platelet binding that occurs as part of the normal thrombosis pathways may further act to allow the coalescence of tumour cells into the VWF-Platelet to form heteroaggregates of VWF+platelets+cancer cells which thereby help in the blood borne (haematogenous) spread of tumour cells.
  • This process may at least in part be caused by the ability of cancer cells to translocate to the vessel wall and thereby spread to other organs once the initial binding to VWF and Platelets has occurred.
  • various cancers are known to cause an endotheliopathy with the resultant release of UL-VWF.
  • the tumour triggers the release of UL-VWF that then allows the tethering of platelets and tumour cells and the haematogenous spread of the cancer and the metastatic spread.
  • This cancer induced endotheliopathy also results in an overall increase in the risk of thrombosis in patients with underlying malignancy. Therefore, any treatment aimed at treating an endotheliopathy and inhibiting the binding of platelets and/or tumour cells to VWF would serve a dual purpose of decreasing the risk of malignancy associated thrombosis and also reduce the risk haematogenous metastatic spread.
  • the MMWH-Red may be administered by an administration method selected from the group consisting of: parenteral, subcutaneous, intravenous, intramuscular, intrathecal, intradermal, intraarterial, intraarticular, cutaneous, transcutaneous, subcutaneous, depot form, for example depot injection, intra-osseus, or inhalation.
  • the medium molecular weight heparin administration method is subcutaneous, intravenous or intramuscular.
  • the administration method may be inhalation, optionally via a nebuliser.
  • UFH a nebulised agent in a variety of conditions.
  • Small human studies indicate that nebulised UFH limits pulmonary fibrin deposition, attenuates progression of acute lung injury and hastens recovery (69).
  • Early-phase trials in patients with acute lung injury and related conditions found that nebulised UFH reduced pulmonary dead space, coagulation activation, microvascular thrombosis, improved lung injury and increased time free of ventilatory support (70- 73).
  • nebulised UFH limited progression of lung injury including acute respiratory distress syndrome and accelerated return to home in survivors.
  • the MMWH-Red may be administered by inhalation via a nebuliser.
  • Heparin dosage is typically measured in "Howell Units".
  • One unit of heparin (the "Howell unit") is an amount approximately equivalent to 0.002 mg of pure heparin, which is the quantity required to keep 1 ml of cat's blood fluid for 24 hours at 0 °C.
  • the MMWH-Red may be administered at a bolus does of about 5000 units, followed by about 1200 to about 1600 units per hour optionally delivered by an infusion pump.
  • the MMWH-Red may be administered at a dose of about 18 units/kg to about 5000 units/kg.
  • the MMWH-Red may be administered at a dose of about 100 units/kg to about 800 units/kg.
  • the MMWH-Red may be administered at a dose of about 18 units/kg to about 75 units/kg.
  • the MMWH-Red may be administered at a dose of about 5000 units, about 4000 units, about 3000 units, about 2000 units, about 1000 units or about 500 units every 12 hours.
  • the MMWH-Red may be administered at a dose of about 5000 units every 12 hours.
  • the MMWH-Red may be administered at a dose of about 3 units to about 5000 units, for example from about 6 units to about 4000 units, from about 12 units to about 3000 units, from about 25 units to about 2000 units, from about 50 units to about 1000 units, from about 100 units to about 500 units, or from about 125 units to about 250 units.
  • the reduced medium molecular weight heparin may be administered at a dose of about 18 unit/kg to about 5000 units/kg, for example from about 100 units/kg to about 4000 units per/kg, or from about 200 units/kg to about 800 units/kg.
  • the reduced medium molecular weight heparin may be administered at a dose of about 18 units/kg to about 75 units/kg.
  • the dose may be given as a single dose or as a continuous dose.
  • the dose may be given over a period of time. The period of time may be from about 1 month to about 12 months, for example from about 2 months to about 11 months, from about 3 months to about 10 months, from about 4 months to about 9 months, from about 5 months to about 8 months, from about 6 months to about 7 months.
  • the period of time may be about 1 day to 7 days, about 2 days to about 6 days, about 3 days to about 5 days, about 4 days to about 5 days.
  • the dose may be administered over about 1 hour to about 24 hours, about 2 hours to about 12 hours, about 3 hours to about 6 hours.
  • the dose may be administered for the duration of the underlying endotheliopathy and raised VWF levels.
  • the MMWH-Red may be administered at a dose of about 0.01 mg/kg to about 10 mg/kg, for example at a dose of about 0.05 mg/kg to about 9 mg/kg, about 0.5 mg/kg to about 8 mg/kg, about 1 mg/kg to about 7 mg/kg, about 1.5 mg/kg to about 6 mg/kg, or about 2 mg/kg to about 5 mg/kg.
  • the dose may be given as a single dose or as a continuous dose. The dose may be given over a period of time.
  • the period of time may be from about 1 month to about 12 months, for example from about 2 months to about 11 months, from about 3 months to about 10 months, from about 4 months to about 9 months, from about 5 months to about 8 months, from about 6 months to about 7 months.
  • the period of time may be about 1 day to about 7 days, about 2 days to about 6 days, about 3 days to about 5 days, about 4 days to about 5 days.
  • the dose may be administered over about 1 hour to about 24 hours, about 2 hours to about 12 hours, about 3 hours to about 6 hours.
  • the dose may be administered for the duration of the underlying endotheliopathy and raised VWF levels.
  • the MMWH-Red may be administered at a dose of from about 0.01 mg/kg, from about 0.1 mg/kg, from about 1 mg/kg, from about 5 mg/kg, from about 10 mg/kg, from about 20 mg/kg, from about 30 mg/kg, from about 50 mg/kg, from about 70 mg/kg, from about 80 mg/kg, or from about 100 mg/kg.
  • the MMWH-Red may be administered at a dose of about 500 mg/kg or less, about 300 mg/kg or less, about 200 mg/kg or less, or about 100 mg/kg or less.
  • the MMWH-Red may be administered at a dose of from about 0.01 mg/kg to about 10 mg/kg, preferably from about 0.2 mg/kg to about 10 mg/kg, from about 0.2 mg/kg to about 1.6 mg/kg.
  • the MMWH-Red may be administered as a single dose or as a continuous dose.
  • the MMWH-Red dosage amount may be dependent on the VWF antigen: ADAMTS13 ratio or the overall VWF levels. The skilled person would be able select a suitable amount for a patient based on the VWF antigen: ADAMTS13 ratio or the overall VWF levels.
  • the MMWH-Red may be administered at a dose of from about 0.01 mg/kg to about 10 mg/kg, from about 0.05 mg/kg to about 8 mg/kg, from about 0.1 mg/kg to about 5 mg/kg, from about 0.5 mg/kg to about 2 mg/kg, from about 1 mg/kg to about 1.5 mg/kg.
  • the dose may be given as a single dose or as a continuous dose.
  • the dose may be given over a period of time.
  • the period of time may be from about 1 month to about 12 months, for example from about 2 months to about 11 months, from about 3 months to about 10 months, from about 4 months to about 9 months, from about 5 months to about 8 months, from about 6 months to about 7 months.
  • the period of time may be from about 1 day to about 7 days, from about 2 days to about 6 days, from about 3 days to about 5 days, from about 4 days to about 5 days.
  • the dose may be administered over about 1 hour to about 24 hours, about 2 hours to about 12 hours, about 3 hours to about 6 hours.
  • the dose may be administered for the duration of the underlying endotheliopathy and raised VWF levels.
  • the MMWH-Red may be administered at a dose of from about 0.1 mg to about 5000 mg, from about 0.5 mg to about 2000 mg, from about 1 mg to about 1000 mg, from about 5 mg to about 900 mg, from about 10 mg to about 800 mg, from about 20 mg to about 700 mg, from about 30 mg to about 600 mg, from about 50 mg to about 500 mg, from about 75 mg to about 400 mg, from about 100 mg to about 300 mg, from about 125 mg to about 250 mg, from about 150 mg to about 200 mg.
  • the dose may be given as a single dose or as a continuous dose. The dose may be given over a period of time.
  • the period of time may be from about 1 month to about 12 months, for example from about 2 months to about 11 months, from about 3 months to about 10 months, from about 4 months to about 9 months, from about 5 months to about 8 months, from about 6 months to about 7 months.
  • the period of time may be from about 1 day to about 7 days, from about 2 days to about 6 days, from about 3 days to about 5 days, from about 4 days to about 5 days.
  • the dose may be administered over about 1 hour to about 24 hours, about 2 hours to about 12 hours, about 3 hours to about 6 hours.
  • the dose may be administered for the duration of the underlying endotheliopathy and raised VWF levels.
  • the MMWH-Red may be administered at a dose of, for example about 1 international units (IU), about 2 I U, about 5 I U, about 10 I U, about 15 I U, about 20 I U, about 25 I U, about 50 I U, about 75 I U, about 100 IU, about 200 IU, about 300 IU, about 400 IU, about 500 IU, about 1000 IU, about 1500 I U, about 2000 I U, about 2500 I U, about 5000 I U, about 10000 I U, about 20000 I U, or about 25 000 IU.
  • the dose may be given as a single dose or as a continuous dose. The dose may be given over a period of time.
  • the period of time may be from about 1 month to about 12 months, for example from about 2 months to about 11 months, from about 3 months to about 10 months, from about 4 months to about 9 months, from about 5 months to about 8 months, from about 6 months to about 7 months.
  • the period of time may be from about 1 day to about 7 days, from about 2 days to about 6 days, from about 3 days to about 5 days, from about 4 days to about 5 days.
  • the dose may be administered over about 1 hour to about 24 hours, about 2 hours to about 12 hours, about 3 hours to about 6 hours.
  • the dose may be administered for the duration of the underlying endotheliopathy and raised VWF levels.
  • the MMWH-Red may be administered at a dose of from about 1 IU to about 50000 IU, from about 2 IU to about 25 000 IU, from about 5 IU to about 20000 IU, from about 10 IU to about 10000 IU, from about 15 IU to about 5000 IU, from about 20 IU to about 2500 IU, from about 25 IU to about 2000 IU, from about 50 IU to about 1500 IU, from about 75 IU to about 1000 IU, from about 100 IU to about 500 IU, from about 200 IU to about 400 IU, from about 250 IU to about 300 IU.
  • the dose may be given as a single dose or as a continuous dose. The dose may be given over a period of time.
  • the period of time may be from about 1 month to about 12 months, for example from about 2 months to about 11 months, from about 3 months to about 10 months, from about 4 months to about 9 months, from about 5 months to about 8 months, from about 6 months to about 7 months.
  • the period of time may be from about 1 day to about 7 days, from about 2 days to about 6 days, from about 3 days to about 5 days, from about 4 days to about 5 days.
  • the dose may be administered over about 1 hour to about 24 hours, about 2 hours to about 12 hours, about 3 hours to about 6 hours.
  • the dose may be administered for the duration of the underlying endotheliopathy and raised VWF levels.
  • the MMWH-Red may be administered that is commensurate with the VWF antigen: ADAMTS13 ratio.
  • a patient with a high VWF antigen: ADAMTS13 ratio may be administered a higher dose of MMWH compared to a patient with a VWF antigen: ADAMTS13 ratio that is lower.
  • the MMWH-Red may be comprised in a pharmaceutical formulation.
  • the pharmaceutical formulation may comprise an excipient.
  • the excipient may be selected from the group comprising solvents, co-solvents, buffers, stabilisers, antioxidants, preservatives, chelating agents, emulsifiers, flavourings, lubricants, suspending agents, tonicity adjusting agents, surfactants, solubilising agents, suspending aids, dispersion agents, humectants, thickeners, colouring agent, wetting agent, anti- foaming agent, viscosity modifier, sweeteners and combinations thereof.
  • the pharmaceutical formulation may comprise an additional active agent.
  • the additional active agent may comprise medium molecular weight heparin or low molecular weight heparin.
  • the pharmaceutical formulation may comprise an additional active agent.
  • the additional active agent comprises a composition of matter that has a physiological effect.
  • the additional active agent may comprise low molecular weight heparin or a medium molecular weight heparin or a reduced medium molecular weight heparin of a different disaccharide composition.
  • the additional active agent may be selected from the group comprising farnesoid X receptor (FXR) agonist, a peroxisome proliferator-activator receptor (PPAR) agonist, aramchol, a caspase inhibitor, a galectin 3 inhibitor, a mitogen-activated protein kinase 5 (MAPK5) inhibitor, a fibroblast growth factor 19 (FGF19) agonist, a FGF21 agonist, a leukotriene D4 (LTD4) receptor antagonist, a niacin analog, an apical sodium bile acid cotransporter (ASBT) inhibitor, an apoptosis signal regulating kinase 1 (ASK1) inhibitor, an angiotensin converting enzyme (ACE) inhibitor, an angiotensin receptor blocker, a chemokine receptor inhibitor, a thiozolidinedione, a GLP-1 analog, a biguanide, an HIV replication inhibitor, metoformin, an opiate, an ana
  • the MMWH-Red may comprise a chemical modification.
  • the chemical modification may be selected from the group comprising N-acetylation, N-deacetylation, N-sulfation, O-sulfation, 2-0 desulfation, and complete desulfation.
  • the invention provides MMWH-Red for use in the treatment of a disease or condition in a patient, wherein the patient has an endotheliopathy characterised by a plasma von Willebrand factor to ADAMTS13 (VWF:ADAMTS13) ratio of at least about 2.
  • VWF:ADAMTS13 plasma von Willebrand factor to ADAMTS13
  • the invention provides MMWH-Red for use in the treatment of a disease or condition in a patient, wherein the patient has an endotheliopathy characterised by a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • VWF antigen:ADAMTS13 a plasma von Willebrand factor antigen to ADAMTS13
  • the disease or condition is selected from the group consisting of: COVID-19, viral infection, acute respiratory distress syndrome (ARDS), cancer, bacterial infection, septicaemia, sepsis, cardiovascular disease, diabetes mellitus, trauma, in particular brain or head trauma, burns, inhalational injury, drugs and drug reactions, haematological conditions, subarachnoid haemorrhage, aneurysmal diseases, stroke, or brain parenchymal haemorrhage or combinations thereof.
  • ARDS acute respiratory distress syndrome
  • cancer bacterial infection
  • septicaemia sepsis
  • cardiovascular disease diabetes mellitus
  • trauma in particular brain or head trauma
  • burns inhalational injury
  • drugs and drug reactions haematological conditions
  • subarachnoid haemorrhage aneurysmal diseases
  • stroke or brain parenchymal haemorrhage or combinations thereof.
  • the endotheliopathy may be caused by a viral infection, optionally wherein the viral infection is SARS-CoV-
  • the endotheliopathy may be caused by cancer, in particular leukaemia, lymphoma, myeloma, or a solid organ cancer, such as colon cancer, breast cancer, brain cancer, lung cancer, pancreatic cancer, testicular cancer, prostate cancer, cervical cancer, liver cancer, or skin cancer.
  • cancer in particular leukaemia, lymphoma, myeloma, or a solid organ cancer, such as colon cancer, breast cancer, brain cancer, lung cancer, pancreatic cancer, testicular cancer, prostate cancer, cervical cancer, liver cancer, or skin cancer.
  • the endotheliopathy is caused by sepsis or septicaemia.
  • the endotheliopathy is caused by sepsis.
  • the present invention provides MMWH-Red for use in the treatment of COVID-19 in a patient, wherein the patient has an endotheliopathy characterised by a plasma VWF:ADAMTS13 ratio of at least about 2 or a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • the present invention provides MMWH-Red for use in the treatment of viral infection in a patient, wherein the patient has an endotheliopathy characterised by a VWF:ADAMTS13 ratio of at least about 2 or a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • the viral infection may be SARS-CoV-2.
  • the present invention provides MMWH-Red for use in the treatment of acute respiratory distress syndrome (ARDS) in a patient, wherein the patient has an endotheliopathy characterised by a plasma VWF:ADAMTS13 ratio of at least about 2 or a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • ARDS acute respiratory distress syndrome
  • VWF antigen:ADAMTS13 plasma von Willebrand factor antigen to ADAMTS13
  • the present invention provides MMWH-Red for use in the treatment of cancer in a patient, wherein the patient has an endotheliopathy characterised by a VWF:ADAMTS13 ratio of at least about 2 or a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • the cancer may be leukaemia, lymphoma, myeloma, or a solid organ cancer, such as colon cancer, breast cancer, brain cancer, lung cancer, pancreatic cancer, testicular cancer, prostate cancer, cervical cancer, liver cancer, or skin cancer.
  • the present invention provides MMWH-Red for use in the treatment of bacterial infection in a patient, wherein the patient has an endotheliopathy characterised by a plasma VWF:ADAMTS13 ratio of at least about 2 or a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • the present invention provides MMWH-Red for use in the treatment of septicaemia in a patient, wherein the patient has an endotheliopathy characterised by a plasma VWF:ADAMTS13 ratio of at least about 2 or a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • the present invention provides MMWH-Red for use in the treatment of sepsis in a patient, wherein the patient has an endotheliopathy characterised by a plasma VWF:ADAMTS13 ratio of at least about 2 or a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • endotheliopathy characterised by a plasma VWF:ADAMTS13 ratio of at least about 2 or a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • the present invention provides MMWH-Red for use in the treatment of cardiovascular disease in a patient, wherein the patient has an endotheliopathy characterised by a plasma VWF:ADAMTS13 ratio of at least about 2 or a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • endotheliopathy characterised by a plasma VWF:ADAMTS13 ratio of at least about 2 or a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • the present invention provides MMWH-Red for use in the treatment of diabetes mellitus in a patient, wherein the patient has an endotheliopathy characterised by a plasma VWF:ADAMTS13 ratio of at least about 2 or a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • endotheliopathy characterised by a plasma VWF:ADAMTS13 ratio of at least about 2 or a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • the present invention provides MMWH-Red for use in the treatment of trauma in a patient, wherein the patient has an endotheliopathy characterised by a plasma VWF:ADAMTS13 ratio of at least about 2 or a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • the trauma is brain trauma or head trauma.
  • the present invention provides MMWH-Red for use in the treatment of burns in a patient, wherein the patient has an endotheliopathy characterised by a plasma VWF:ADAMTS13 ratio of at least about 2 or a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • the present invention provides MMWH-Red for use in the treatment of inhalational injury in a patient, wherein the patient has an endotheliopathy characterised by a plasma VWF:ADAMTS13 ratio of at least about 2 or a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • endotheliopathy characterised by a plasma VWF:ADAMTS13 ratio of at least about 2 or a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • the present invention provides MMWH-Red for use in the treatment of drug reactions in a patient, wherein the patient has an endotheliopathy characterised by a plasma VWF:ADAMTS13 ratio of at least about 2 or a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • the present invention provides MMWH-Red for use in the treatment of haematological conditions in a patient, wherein the patient has an endotheliopathy characterised by a plasma VWF:ADAMTS13 ratio of at least about 2 or a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • endotheliopathy characterised by a plasma VWF:ADAMTS13 ratio of at least about 2 or a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • the present invention provides MMWH-Red for use in the treatment of subarachnoid haemorrhage in a patient, wherein the patient has an endotheliopathy characterised by a plasma VWF:ADAMTS13 ratio of at least about 2 or a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • the present invention provides MMWH-Red for use in the treatment of aneurysmal diseases in a patient, wherein the patient has an endotheliopathy characterised by a plasma VWF:ADAMTS13 ratio of at least about 2 or a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • MMWH-Red for use in the treatment of endotheliopathy as defined in the seventh, eighth or ninth aspect of the invention are particularly advantageous as said heparins can inhibit the microthrombosis triggered by the release of VWF secondary to the endotheliopathy caused by any disease or condition.
  • said MMWH-Red can additionally inhibit viral adherence and replication.
  • the invention provides a method of treating endotheliopathy, the method comprising administering to a subject in need of treatment a therapeutically effective amount of MMWH-Red.
  • the patient has plasma VWF:ADAMTS13 ratio of at least about 2 or a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • the invention provides the use of the MMWH-Red for the manufacture of a medicament for the treatment of endotheliopathy in a patient.
  • the patient has plasma VWF:ADAMTS13 ratio of at least about 2 or a plasma von Willebrand factor antigen to ADAMTS13 (VWF antigen:ADAMTS13) ratio of at least about 2.
  • Sepsis is the body's extreme response to an infection. It is characterised by a whole-body inflammatory state where as a result of immune response dysregulation, the immune system reacts to the infection by attacking the body's own tissues and organs. Consequently, cells in the body are destroyed through apoptosis or necrosis and intracellular material ends up in the blood stream.
  • Histones are intracellular basic proteins found in the nucleus of a cell. DNA wraps itself around histones to form chromatin, which is then itself tightly wound to facilitate the packaging of the long DNA molecule into the nucleus of the cell. Whilst known for its role in the packaging of DNA into the nucleus, chromatin (and its constituent histones) have also been shown to play a role in innate immunity. During infection, neutrophils release granular proteins and chromatin that together form extracellular fibres that bind Gram positive and negative bacteria. These neutrophil extracellular traps (NETs) degrade virulence factors and kill bacteria.
  • NETs neutrophil extracellular traps
  • Circulating histones have been identified as mediators of damage in animal models of sepsis and in patients. These histones may enter the bloodstream as a result of intracellular material being released due to apoptosis or necrosis which occurs during sepsis, or via NET release in response to bacterial infection. Accordingly, histones may propagate the dysregulation of the immune system observed during sepsis. For example, histones are damage associated molecule patterns (DAMPs) which are sensed by toll-like receptors (TLRs). Activation of TLRs on innate immune cells by histones results in the release of pro-inflammatory cytokines, thereby exacerbating an already dysregulated immune response.
  • DAMPs damage associated molecule patterns
  • TLRs toll-like receptors
  • TLR receptors on endothelial cells may be activated by circulating histones, which results in the induction of an immune response in the endothelial cells.
  • the endothelium becomes inflamed and endothel ialitis and endotheliopathy is observed.
  • the MMWH or MMWH-Red as defined herein may bind to free histones whilst simultaneously inhibiting VWF, thereby treating sepsis.
  • the invention provides MMWH or MMWH-Red for the treatment of sepsis, systemic Inflammatory response syndrome (SIRS), severe sepsis or septic shock in a subject.
  • the subject has plasma VWF:ADAMTS13 ratio of at least about 2.
  • the MMWH or MMWH-Red as defined herein may be a complement cascade modulator.
  • the MMWH or MMWH-Red as defined herein may be an immune modulator.
  • room temperature and pressure are 20 °C (293.15 K, 68 °F) and 1 atm (14.696 psi, 101.325 kPa), respectively.
  • SEC is performed on a GEC Superdex75 (10/100) column on an Agilent 1200 HPLC system with variable wavelength UV monitor or GEC AKTA system with variable wavelength UV monitor.
  • the mobile phase is 0.15M NaCI in water, which is passed through the column at 0.4 mL/min.
  • the optical density is measured at 232 nm.
  • SEC is performed with reference to an 11 kD standard.
  • Freeze drying is a drying process carried out at low temperature. Freeze drying generally involves reducing temperature and pressure to below the substance's triple point and removing the frozen solvent (e.g. water ice) by sublimation. For aqueous compositions, such as those disclosed herein, freeze drying may be carried out at temperatures of from about -20 °C to -80 °C, preferably about -40 °C, and pressures of from about 1000 Pa (0.01 bar) to about 10 Pa (0.0001 bar).
  • freeze drying may be carried out at temperatures of from about -20 °C to -80 °C, preferably about -40 °C, and pressures of from about 1000 Pa (0.01 bar) to about 10 Pa (0.0001 bar).
  • Samples were prepared with (A) 43 mg, (B) 86 mg, (C) 173 mg or (D) 200 mg sodium periodate added to the heparin in sodium phosphate buffer solution. The resultant solutions were incubated at 4 °C for 16 to 18 hours or at 37 °C for 6 hours.
  • Figure 1 shows MMWH prepared at 4 °C compared to heparin treated at 37 °C, untreated heparin and a 11 kDa standard.
  • Figure 2 shows MMWH prepared at 4 °C using only periodate compared to heparin treated with periodate then NaOH at 4 °C, which runs as a broad peak due to degradation. Accordingly, the preparation of high purity medium molecular weight heparin is impeded by the inclusion of an alkaline elimination step as significant degradation is observed.
  • the medium molecular weight heparin sample was then dissolved in water and analysed by SEC on Superdex® 75 SE (10/300) column in 0.15M NaCI at 0.4mL/min on either a GEC AKTA system or an Agilent 1200 system.
  • the medium molecular weight heparin had an average molecular weight of 11 kDa with reference to a 11 kDa standard as shown in Figure 3.
  • the medium molecular weight heparin produced displayed very low activity against Factor Ila and/or Xa as compared to UF heparin and low molecular weight heparin.
  • MMW Heparin does not affect Factor Ila or Factor Xa- mediated coagulation.
  • Factor Ila acts as a serine protease that converts soluble fibrogen into insoluble strands of fibrin, as well as catalysing other coagulation-related reactions.
  • Factor Xa is the activated form of the coagulation factor X.
  • Factor X is an serine endopeptidase enzyme, which plays a key role at several stages of the coagulation system.
  • Heparin unfractionated heparin
  • its derivatives e.g. low molecular weight heparin
  • AT antithrombin
  • This inactivation of Factor Xa by heparins is termed "indirect” since it relies on the presence of AT and not a direct interaction with Factor Xa.
  • Activity against Factor Ila and Factor Xa can be measured using Kinetichrome Anti-lla Heparin Kit and Kinetichrome Anti-Xa Heparin Kit, respectively.
  • UF Heparin of Porcine mucosal origin is used for the purposes of the example synthesis provided herewith.
  • other sources of UF heparin are suitable for use in the methods disclosed herein.
  • Gralinski LE Baric RS. Molecular pathology of emerging coronavirus infections. J Pathol. 2015 Jan;235(2):185-95.
  • ADAMTS13 activity is associated with an increased risk of ischemic stroke. Blood. 2015 Dec 17;126(25):2739-46.
  • Coagulation markers are independent predictors of increased oxygen requirements and thrombosis in COVID-19. J Thromb Haemost. 2020;18(12):3382-4.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La présente invention concerne la synthèse d'héparines à poids moléculaire moyen.
PCT/EP2023/082300 2022-11-17 2023-11-17 Préparation d'héparine à poids moléculaire moyen WO2024105271A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2217216.7 2022-11-17
GBGB2217216.7A GB202217216D0 (en) 2022-11-17 2022-11-17 Preparation of medium molecular weight heparin

Publications (1)

Publication Number Publication Date
WO2024105271A1 true WO2024105271A1 (fr) 2024-05-23

Family

ID=84888957

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/082300 WO2024105271A1 (fr) 2022-11-17 2023-11-17 Préparation d'héparine à poids moléculaire moyen

Country Status (2)

Country Link
GB (1) GB202217216D0 (fr)
WO (1) WO2024105271A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017187A1 (fr) * 1991-03-29 1992-10-15 Glycomed, Inc. Nouveaux derives de l'heparine non anti-coagulants
EP0735050B1 (fr) * 1995-03-31 2002-09-25 Hamilton Civic Hospitals Research Development, Inc. Compositions pour inhibiter la thrombogénèse
JP2006347883A (ja) * 2003-09-08 2006-12-28 Neetec:Kk 糖鎖含有キトサン誘導体及びグリコサミノグリカンを含有する医療用組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017187A1 (fr) * 1991-03-29 1992-10-15 Glycomed, Inc. Nouveaux derives de l'heparine non anti-coagulants
EP0735050B1 (fr) * 1995-03-31 2002-09-25 Hamilton Civic Hospitals Research Development, Inc. Compositions pour inhibiter la thrombogénèse
JP2006347883A (ja) * 2003-09-08 2006-12-28 Neetec:Kk 糖鎖含有キトサン誘導体及びグリコサミノグリカンを含有する医療用組成物

Non-Patent Citations (76)

* Cited by examiner, † Cited by third party
Title
ANGUS DCVAN DER POLL T: "Severe sepsis and septic shock", N ENGL J MED, vol. 369, no. 9, 29 August 2013 (2013-08-29), pages 840 - 51
ARYA M, ANVARI B, ROMO GM, CRUZ MA, DONG J-F, MCINTIRE LV, ET AL.: "Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex:studies using optical tweezers", BLOOD, vol. 99, no. 11, 1 June 2002 (2002-06-01), pages 3971 - 7
ATAM VSINGH ASYATHISH BEDAS L: "Acute pancreatitis and acute respiratory distress syndrome complicating Plasmodium vivax malaria", J VECTOR BORNE DIS, vol. 50, no. 2, June 2013 (2013-06-01), pages 151 - 4
BERNARDO ABALL CNOLASCO LMOAKE JFDONG J.: "Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow", BLOOD, vol. 104, no. 1, 1 July 2004 (2004-07-01), pages 100 - 6
BHOGAL P, JENSEN M, COLLINS G, SPOONER O, MAKALANDA L, HART D, ET AL.: "Coagulation markers are independent predictors of increased oxygen requirements and thrombosis in COVID-19", J THROMB HAEMOST, vol. 18, no. 12, 2020, pages 3382 - 4
BONGERS TNDE BRUIJNE ELEDIPPEL DWJDE JONG AJDECKERS JWPOLDERMANS D ET AL.: "Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients", ATHEROSCLEROSIS, vol. 207, no. 1, November 2009 (2009-11-01), pages 250 - 4
BONGERS TNDE MAAT MPMVAN GOOR M-LPJBHAGWANBALI VVAN VLIET HHDMGOMEZ GARCIA EB ET AL.: "High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability", STROKE, vol. 37, no. 11, November 2006 (2006-11-01), pages 2672 - 7, XP055081768, DOI: 10.1161/01.STR.0000244767.39962.f7
BONGERS TNEMONTS MDE MAAT MPMDE GROOT RLISMAN THAZELZET JA ET AL.: "Reduced ADAMTS13 in children with severe meningococcal sepsis is associated with severity and outcome", THROMB HAEMOST, vol. 103, no. 6, June 2010 (2010-06-01), pages 1181 - 7
CHANG JC: "Disseminated intravascular coagulation: is it fact or fancy?", BLOOD COAGUL FIBRINOLYSIS INT J HAEMOST THROMB, vol. 29, no. 3, April 2018 (2018-04-01), pages 330 - 7
CHANG JC: "Hemostasis based on a novel ''two-path unifying theory'' and classification of hemostatic disorders", BLOOD COAGUL FIBRINOLYSIS INT J HAEMOST THROMB, vol. 29, no. 7, November 2018 (2018-11-01), pages 573 - 84
CHANG JC: "Sepsis and septic shock: endothelial molecular pathogenesis associated with vascular microthrombotic disease", THROMB J., vol. 17, no. 10, 2019
CHANG JC: "Thrombogenesis and thrombotic disorders based on ''two-path unifying theory of hemostasis'': philosophical, physiological, and phenotypical interpretation", BLOOD COAGUL FIBRINOLYSIS INT J HAEMOST THROMB, vol. 29, no. 7, November 2018 (2018-11-01), pages 585 - 95
CHANG JC: "TTP-like syndrome: novel concept and molecular pathogenesis of endotheliopathy-associated vascular microthrombotic disease", THROMB J., vol. 16, 2018, pages 20
CHEN NZHOU MDONG XQU JGONG FHAN Y ET AL.: "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study", LANCET LOND ENGL, vol. 15, no. 10223, 2020, pages 507 - 13, XP086050323, DOI: 10.1016/S0140-6736(20)30211-7
CICERI FBERETTA LSCANDROGLIO AMCOLOMBO SLANDONI GRUGGERI A ET AL.: "Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis", CRIT CARE RESUSC J AUSTRALAS ACAD CRIT CARE MED, 15 April 2020 (2020-04-15)
CLAUSEN TMSANDOVAL DRSPLIID CBPIHL JPERRETT HRPAINTER CD ET AL.: "SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2", CELL, vol. 183, no. 4, 12 November 2020 (2020-11-12), pages 1043 - 1057
COHEN JVINCENTJ-LADHIKARI NKJMACHADO FRANGUS DCCALANDRA T ET AL.: "Sepsis: a roadmap for future research", LANCET INFECT DIS, vol. 15, no. 5, May 2015 (2015-05-01), pages 581 - 614
DANZI GBLOFFI MGALEAZZI GGHERBESI E: "Acute pulmonary embolism and COVID-19 pneumonia: a random association?", EUR HEART J., 30 March 2020 (2020-03-30)
DE VRIES PSVAN HERPT TTWLIGTHART SHOFMAN AIKRAM MAVAN HOEK M ET AL.: "ADAMTS13 activity as a novel risk factor for incident type 2 diabetes mellitus: a population-based cohort study", DIABETOLOGIA, vol. 60, no. 2, 2017, pages 280 - 6, XP036122762, DOI: 10.1007/s00125-016-4139-5
DIXON BCAMPBELL DJSANTAMARIA JD: "Elevated pulmonary dead space and coagulation abnormalities suggest lung microvascular thrombosis in patients undergoing cardiac surgery", INTENSIVE CARE MED, vol. 34, no. 7, July 2008 (2008-07-01), pages 1216 - 23, XP037136258, DOI: 10.1007/s00134-008-1042-7
DIXON BSCHULTZ MJHOFSTRA JJCAMPBELL DJSANTAMARIA JD: "Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury", CRIT CARE LOND ENGL., vol. 14, no. 5, 2010, pages 445
DIXON BSCHULTZ MJSMITH RFINK JBSANTAMARIA JDCAMPBELL DJ: "Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial", CRIT CARE LOND ENGL., vol. 14, no. 5, 2010, pages R180, XP021085545, DOI: 10.1186/cc9286
DIXON BSMITH RSANTAMARIA JDORFORD NRWAKEFIELD BJIVES K ET AL.: "A trial of nebulised heparin to limit lung injury following cardiac surgery", ANAESTH INTENSIVE CARE, vol. 44, no. 1, January 2016 (2016-01-01), pages 28 - 33
DIZIER S, FOREL J-M, AYZAC L, RICHARD J-C, HRAIECH S, LEHINGUE S, ET AL.: " Early Hepatic Dysfunction Is Associated with a Worse Outcome in Patients Presenting with Acute Respiratory Distress Syndrome:A Post-Hoc Analysis of the ACURASYS and PROSEVA Studies.", PLOS ONE, vol. 10, no. 12, 2015, pages e0144278
DONG JMOAKE JLNOLASCO LBERNARDO AARCENEAUX WSHRIMPTON CN ET AL.: "ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions", BLOOD, vol. 100, no. 12, 1 December 2002 (2002-12-01), pages 4033 - 9, XP008126520, DOI: 10.1182/blood-2002-05-1401
ESCHER RBREAKEY NLAMMLE B: "Severe COVID-19 infection associated with endothelial activation", THROMB RES, vol. 190, no. 62, 15 April 2020 (2020-04-15)
FOX SEAKMATBEKOV AHARBERT JLLI GBROWN JQHEIDE RSV: "Pulmonary and Cardiac Pathology in Covid-19: The First Autopsy Series from New Orleans", MEDRXIV, 10 April 2020 (2020-04-10)
GAO YLI THAN MLI XWU DXU Y ET AL.: "Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19", J MED VIROL., 17 March 2020 (2020-03-17)
GATTINONI LCOPPOLA SCRESSONI MBUSANA MROSSI SCHIUMELLO D: "Covid-19 Does Not Lead to a ''Typical'' Acute Respiratory Distress Syndrome", AM J RESPIR CRIT CARE MED, 30 March 2020 (2020-03-30)
GONZALVO RMARTI-SISTAC OBLANCH LLOPEZ-AGUILAR J: "Bench-to-bedside review: brain-lung interaction in the critically ill--a pending issue revisited", CRIT CARE LOND ENGL, vol. 11, no. 3, 2007, pages 216
GOSHUA GPINE ABMEIZLISH MLCHANG C-HZHANG HBAHEL P ET AL.: "Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study", LANCET HAEMATOL [INTERNET, 30 June 2020 (2020-06-30)
GOUDOT GCHOCRON RAUGY J-LGENDRON NKHIDER LDEBUC B ET AL.: "Predictive Factor for COVID-19 Worsening: Insights for High-Sensitivity Troponin and D-Dimer and Correlation With Right Ventricular Afterload", FRONT MED, vol. 7, 2020, pages 586307
GRALINSKI LEBARIC RS: "Molecular pathology of emerging coronavirus infections", J PATHOL, vol. 235, no. 2, January 2015 (2015-01-01), pages 185 - 95, XP055843696, DOI: 10.1002/path.4454
GU SEAN X ET AL: "Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation", NATURE REVIEWS CARDIOLOGY, 9 March 2021 (2021-03-09), pages 194 - 209, XP037373980, ISSN: 1759-5002, Retrieved from the Internet <URL:https://www.nature.com/articles/s41569-020-00469-1#:~:text=A%20complex%20interaction%20between%20coagulopathy,diabetes%20mellitus%2C%20obesity%20and%20ageing.> [retrieved on 20240223], DOI: 10.1038/S41569-020-00469-1 *
HELMS JTACQUARD CSEVERAC FLEONARD-LORANT IGHANA MDELABRANCHE X ET AL.: "High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study", INTENSIVE CARE MED, vol. 46, no. 6, 2020, pages 1089 - 98, XP037168785, DOI: 10.1007/s00134-020-06062-x
HERNANDEZ-FERNANDEZ FSANDOVAL VALENCIA HBARBELLA-APONTE RACOLLADO-JIMENEZ RAYO-MARTIN OBARRENA C ET AL.: "Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description", BRAIN, vol. 143, no. 10, 1 October 2020 (2020-10-01), pages 3089 - 103
HUANG CWANG YLI XREN LZHAO JHU Y ET AL.: "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", LANCET LOND ENGL., vol. 15, no. 10223, 2020, pages 497 - 506, XP086050317, DOI: 10.1016/S0140-6736(20)30183-5
HUANGJROTH RHEUSER JESAD!ERJE: "Integrin alpha(v)beta(3) on human endothelial cells binds von Willebrand factor strings under fluid shear stress", BLOOD, vol. 113, no. 7, 12 February 2009 (2009-02-12), pages 1589 - 97
HUISMAN ABEUN RSIKMA MWESTERINK JKUSADASI N: "Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS-CoV-2", INT J LAB HEMATOL, vol. 42, no. 5, October 2020 (2020-10-01), pages 211 - 2
JOHANSEN MEJOHANSSON PIOSTROWSKI SRBESTLE MHHEIN LJENSEN ALG ET AL.: "Profound endothelial damage predicts impending organ failure and death in sepsis", SEMIN THROMB HEMOST, vol. 41, no. 1, February 2015 (2015-02-01), pages 16 - 25
JUNG EMSTROSZCZYNSKI CJUNG F: "Contrast enhanced ultrasonography (CEUS) to detect abdominal microcirculatory disorders in severe cases of COVID-19 infection: First experience", CLIN HEMORHEOL MICROCIRC, 23 April 2020 (2020-04-23)
LADIKOU EESIVALOGANATHAN HMILNE KMARTER WERAMASAMY RSAAD R ET AL.: "Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19?", CLIN MED LOND ENGL, 21 July 2020 (2020-07-21)
LI TSGOMERSALL CDJOYNT GMCHAN DPSLEUNG PHUI DSC: "Long-term outcome of acute respiratory distress syndrome caused by severe acute respiratory syndrome (SARS): an observational study", CRIT CARE RESUSC J AUSTRALAS ACAD CRIT CARE MED, vol. 8, no. 4, December 2006 (2006-12-01), pages 302 - 8
LIPPI GPLEBANI MHENRY BM: "Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis", CLIN CHIM ACTA INT J CLIN CHEM., vol. 506, 13 March 2020 (2020-03-13), pages 145 - 8
LIPPI GWONG JHENRY BM: "Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): a pooled analysis", POL ARCH INTERN MED, 31 March 2020 (2020-03-31)
LIU LCHOPRA PLI XBOUWMAN KMTOMPKINS SMWOLFERT MA ET AL.: "Heparan sulfate proteoglycans as attachment factor for SARS-CoV-2", BIORXIV, 4 January 2021 (2021-01-04)
MANCINI IBARONCIANI LARTONI ACOLPANI PBIGANZOLI MCOZZI G ET AL.: "The ADAMTS13-von Willebrand factor axis in COVID-19 patients", J THROMB HAEMOST JTH, 23 November 2020 (2020-11-23)
NAMENDYS-SILVA SA: "Respiratory support for patients with COVID-19 infection", LANCET RESPIR MED., vol. 8, no. 4, 2020, pages e18
OSTROWSKI SRHAASE NMULLER RBMOLLER MHPOTT FCPERNER A ET AL.: "Association between biomarkers of endothelial injury and hypocoagulability in patients with severe sepsis: a prospective study", CRIT CARE LOND ENGL., vol. 19, 24 April 2015 (2015-04-24), pages 191, XP021221742, DOI: 10.1186/s13054-015-0918-5
PADILLA AMOAKE JLBERNARDO ABALL CWANG YARYA M ET AL.: "P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface", BLOOD, vol. 103, no. 6, 15 March 2004 (2004-03-15), pages 2150 - 6
PANIGADA MBOTTINO NTAGLIABUE PGRASSELLI GNOVEMBRINO CCHANTARANGKUL V ET AL.: "Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis", J THROMB HAEMOST JTH, 17 April 2020 (2020-04-17)
PHILIPPE ACHOCRON RGENDRON NBORY OBEAUVAIS APERON N ET AL.: "Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality", ANGIOGENESIS, no. 1-13, 15 January 2021 (2021-01-15)
POLETTI LFBIRD KEMARQUES DHARRIS RBSUDA YSOBEL M: "Structural aspects of heparin responsible for interactions with von Willebrand factor", ARTERIOSCLER THROMB VASC BIOL, vol. 17, no. 5, May 1997 (1997-05-01), pages 925 - 31
RAUCH ALABREUCHE JLASSALLE FGOUTAY JCAPLAN MCHARBONNIER L ET AL.: "Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID-19", J THROMB HAEMOST, 26 August 2020 (2020-08-26)
ROTZINGER DCBEIGELMAN-AUBRY CVON GARNIER CQANADLI SD: "Pulmonary embolism in patients with COVID-19: Time to change the paradigm of computed tomography", THROMB RES, vol. 190, 11 April 2020 (2020-04-11), pages 58 - 9
SEDAGHAT SDE VRIES PSBOENDER JSONNEVELD MAHHOORN EJHOFMAN A ET AL.: "von Willebrand Factor, ADAMTS13 Activity, and Decline in Kidney Function: A Population-Based Cohort Study", AM J KIDNEY DIS OFF J NATL KIDNEY FOUND, vol. 68, no. 5, November 2016 (2016-11-01), pages 726 - 32, XP029774050, DOI: 10.1053/j.ajkd.2016.05.032
SOBEL MMCNEILL PMCARLSON PLKERMODE JCADELMAN BCONROY R ET AL.: "Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo", J CLIN INVEST., vol. 87, no. 5, May 1991 (1991-05-01), pages 1787 - 93, XP002668650, DOI: 10.1172/JCI115198
SOBEL MSOLER DFKERMODE JCHARRIS RB: "Localization and characterization of a heparin binding domain peptide of human von Willebrand factor", J BIOL CHEM., vol. 267, no. 13, 5 May 1992 (1992-05-05), pages 8857 - 62, XP002276576
SONNEVELD M A. HKAVOUSI MIKRAM MAHOFMAN ARUEDA OCHOA OLTURECEK PL ET AL.: "Low ADAMTS-13 activity and the risk of coronary heart disease - a prospective cohort study: the Rotterdam Study", J THROMB HAEMOST JTH, vol. 14, no. 11, 2016, pages 2114 - 20
SONNEVELD MAHDE MAAT MPMPORTEGIES MLPKAVOUSI MHOFMAN ATURECEK PL ET AL.: "Low ADAMTS13 activity is associated with an increased risk of ischemic stroke", BLOOD, vol. 126, no. 25, 17 December 2015 (2015-12-17), pages 2739 - 46
SONNEVELD MAHFRANCO OHIKRAM MAHOFMAN AKAVOUSI MDE MAAT MPM ET AL.: "Von Willebrand Factor, ADAMTS13, and the Risk of Mortality: The Rotterdam Study", ARTERIOSCLER THROMB VASC BIOL., vol. 36, no. 12, 2016, pages 2446 - 51
TANG NLI DWANG XSUN Z: "Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia", J THROMB HAEMOST JTH, vol. 18, no. 4, 2020, pages 844 - 7, XP055761328, DOI: 10.1111/jth.14768
TEE AWONG AYUSUFF TRAO DSIDHU P: "Contrast-enhanced ultrasound (CEUS) of the lung reveals multiple areas of microthrombi in a COVID-19 patient", INTENSIVE CARE MED, 18 May 2020 (2020-05-18)
TREMBLAY DVAN GERWEN MALSEN MTHIBAUD SKESSLER AJVENUGOPAL S ET AL.: "Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study", BLOOD, 27 May 2020 (2020-05-27)
VAN HAREN FMPPAGE CLAFFEY JGARTIGAS ACAMPRUBI-RIMBLAS MNUNES Q ET AL.: "Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence", CRIT CARE LOND ENGL, vol. 24, no. 1, 22 July 2020 (2020-07-22), pages 454, XP055819084, DOI: 10.1186/s13054-020-03148-2
VARGA ZFLAMMER AJSTEIGER PHABERECKER MANDERMATT RZINKERNAGEL AS ET AL.: "Endothelial cell infection and endotheliitis in COVID-19", THE LANCET [INTERNET, 20 April 2020 (2020-04-20), Retrieved from the Internet <URL:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30937-5/abstract>
VILLACRES SMMEDAR SSAYDIN SI: "Acute Kidney Injury in Children With Acute Respiratory Failure", CLIN PEDIATR (PHILA, vol. 57, no. 11, 2018, pages 1340 - 8
WANG DHU BHU CZHU FLIU XZHANG J ET AL.: "Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China", JAMA, 7 February 2020 (2020-02-07)
WARE LBCONNER ERMATTHAY MAVON WILLEBRAND: "factor antigen is an independent marker of poor outcome in patients with early acute lung injury", CRIT CARE MED, vol. 29, no. 12, December 2001 (2001-12-01), pages 2325 - 31
WARE LBEISNER MDTHOMPSON BTPARSONS PEMATTHAY MA: "Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury", AM J RESPIR CRIT CARE MED, vol. 170, no. 7, 1 October 2004 (2004-10-01), pages 766 - 72
WESTWOOD J-PLANGLEY KHEELAS EMACHIN SJSCULLY M: "Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura", BR J HAEMATOL, vol. 164, no. 6, March 2014 (2014-03-01), pages 858 - 66, XP071121898, DOI: 10.1111/bjh.12707
XIE YWANG XYANG PZHANG S: "COVID-19 Complicated by Acute Pulmonary Embolism", RADIOL CARDIOTHORAC IMAGING, vol. 2, no. 2, 1 April 2020 (2020-04-01), pages e200067
YAMAMOTO KDE WAARD VFEARNS CLOSKUTOFF DJ: "Tissue distribution and regulation of murine von Willebrand factor gene expression in vivo", BLOOD, vol. 92, no. 8, 15 October 1998 (1998-10-15), pages 2791 - 801
YANG MNG MHLLI CK: "Thrombocytopenia in patients with severe acute respiratory syndrome (review", HEMATOL AMST NETH, vol. 10, no. 2, April 2005 (2005-04-01), pages 101 - 5
ZHOU FYU TDU RFAN GLIU YLIU Z ET AL.: "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study", LANCET LOND ENGL, vol. 28, no. 10229, 2020, pages 1054 - 62, XP055954482, DOI: 10.1016/S0140-6736(20)30566-3
ZHU NZHANG DWANG WLI XYANG BSONG J ET AL.: "A Novel Coronavirus from Patients with Pneumonia in China", N ENGL J MED., vol. 20, no. 8, 2019, pages 727 - 33

Also Published As

Publication number Publication date
GB202217216D0 (en) 2023-01-04

Similar Documents

Publication Publication Date Title
Qiu et al. Pharmacological and clinical application of heparin progress: An essential drug for modern medicine
Gandhi et al. Heparin/heparan sulphate-based drugs
Prasad et al. Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A
Fonseca et al. Effects of polysaccharides enriched in 2, 4-disulfated fucose units on coagulation, thrombosis and bleeding
US20170020911A1 (en) Antithrombin-heparin compositions and methods
US20070021378A1 (en) Heparin compositions and selectin inhibition
EP1755620B1 (fr) Derives depolymerises sulfates d&#39;exopolysaccharides (eps), preparation et leurs utilisations
US20040072796A1 (en) Method and composition for preventing pain in sickle cell patients
Fonseca et al. Improved anticoagulant effect of fucosylated chondroitin sulfate orally administered as gastroresistant tablets
JP2008518090A (ja) ヘパリン起因性血小板減少症（ｈｉｔ）症候群の硫酸化多糖類治療のための方法および医薬
Spadarella et al. From unfractionated heparin to pentasaccharide: Paradigm of rigorous science growing in the understanding of the in vivo thrombin generation
Lassila et al. Mast cell–derived heparin proteoglycans as a model for a local antithrombotic
US20120322760A1 (en) Methods of treatment with a low molecular weight heparin composition
WO2021201950A1 (fr) Procédés pour réduire l&#39;apparition d&#39;une thrombose ou d&#39;une thrombo-embolie
Hainer et al. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis
WO2024105271A1 (fr) Préparation d&#39;héparine à poids moléculaire moyen
US20240245718A1 (en) Medium molecular weight heparin for use in the treatment of endotheliopathy
Szczubialka et al. Heparin-a key drug in the treatment of the circulatory degenerative diseases: controlling its action with polymers
Borawski et al. Effect of Sulodexide on Plasma Transforming Growth Factor-β1 in Healthy Volunteers
EP2280984A2 (fr) Galactanes sulfatés à activité antithrombotique, composition pharmaceutique, procédé de traitement ou de prophylaxie des thromboses artérielles ou veineuses, procédé d&#39;extraction et d&#39;utilisation de ces galactanes
Escopy et al. Targeting the P-selectin/PSGL-1 Pathway: Discovery of Disease-Modifying Therapeutics for Disorders of Thromboinflammation
EP3924391A1 (fr) Héparine bovine sûre, procédé de préparation et application
JP2023513656A (ja) Ｐｅｇ－脂質
US20240165150A1 (en) Combination for treatment of thromboinflammation
US20160082051A1 (en) Use of sea cucumber glycosaminoglycan in preparing medicine for prevention and treatment of thromboembolic disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23817958

Country of ref document: EP

Kind code of ref document: A1